

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/85, 5/16, 15/11, 15/63, 15/86	A2	(11) International Publication Number: WO 95/13374 (43) International Publication Date: 18 May 1995 (18.05.95)
(21) International Application Number: PCT/US94/12911 (22) International Filing Date: 8 November 1994 (08.11.94) (30) Priority Data: 08/149,103 8 November 1993 (08.11.93) US (71) Applicant: BAYLOR COLLEGE OF MEDICINE [US/US]; Texas Medical Center, One Baylor Plaza, Houston, TX 77030-3498 (US). (72) Inventor: CHAN, Lawrence, C., B.; 7618 Ludington, Houston, TX 77071 (US). (74) Agents: WEISS, Steven, M. et al.; Lyon & Lyon, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: HUMAN AND MOUSE VERY LOW DENSITY LIPOPROTEIN RECEPTORS AND METHODS FOR USE OF SUCH RECEPTORS		
(57) Abstract Methods of treating diseases or conditions, characterized by elevated serum lipoprotein levels, by providing elevated levels of a VLDL receptor in an animal, e.g., a human are set forth. Such receptors aid in removal of circulating VLDL and related lipoproteins, and thus decrease the risk of developing coronary diseases or conditions or decrease the severity of such diseases or conditions. Clones of human and mouse VLDL receptor which can be used in the invention are also provided. Vectors for the expression of VLDL receptors, stably transfected and transformed cells and transgenic animals are also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DESCRIPTIONHUMAN AND MOUSE VERY LOW DENSITY LIPOPROTEIN
RECEPTORS AND METHODS FOR USE OF SUCH RECEPTORSBackground of the Invention

This invention relates to methods for treatment or prevention of cardiovascular disease.

Cardiovascular disease is the leading cause of death in Western society. A number of factors predispose individuals to premature atherosclerosis, including cigarette smoking, obesity, diabetes mellitus, hypertension, and high plasma cholesterol levels. Atherosclerosis develops when atheromatous plaques form on blood vessels. The lipid deposits in these plaques are derived from circulating plasma lipoproteins. The propensity to develop atherosclerotic cardiovascular disease is directly related to the plasma lipid concentration and distribution, e.g., hyperlipoproteinemia.

The standard treatment modalities for hyperlipoproteinemia include dietary therapy, physical exercise and drug therapy. Dietary therapy occurs in two steps, the Step I and Step II diets, which are designed to progressively reduce intakes of saturated fatty acids (saturated fat) and cholesterol and to promote weight loss in patients who are overweight. Increased physical activity is also an important element in the nonpharmacologic therapy of hyperlipoproteinemia (JAMA 269: 3015-3023, 1993). Currently the drugs recommended for hyperlipoproteinemia can be classified into two classes: Major drugs (bile acid sequestrants, nicotinic acid, and HMGCoA reductase inhibitors); and other drugs (fibrates and probucol). Bile acid sequestrants are recommended for patients with elevated LDL cholesterol.

Nicotinic acid is effective in lowering total cholesterol and triglyceride levels and raising HDL cholesterol levels. Drug therapy is generally used for many years or a lifetime.

5 An alternative form of therapy is extracorporeal removal of LDL. LDL is removed by some physical means (e.g., adsorption to immunoadsorbant, or dextran sulfate, heparin precipitation, filtration, or plasma exchange). This method has been applied to homozygous familial
10 hypercholesterolemia ("FH") FH patients (Gotto et al., Eds., Treatment of Severe Hypercholesterolemia in the Prevention of Coronary Heart Disease-2, Karger Press, pp.1-11, 1990). It is technically and physically demanding and requires special equipment.

15 Once atherosclerosis has developed in an artery or arteriole (e.g., a coronary artery), it either progresses, stabilizes or regresses. Regression occurs rarely, although it has been documented and its frequency appears to be increased by aggressive lipid lowering
20 (Blankenhorn et al., JAMA 257: 3233-3240, 1987; Brown et al., N. Engl. J. Med. 323: 1289-1298, 1990; Kane et al., N. Engl. J. Med. 304: 251-258, 1981). Coronary artery stenosis caused by atherosclerosis can be treated by percutaneous transluminal coronary angioplasty or by
25 coronary bypass surgery.

 The lipoproteins associated with hyperlipoproteinemia are macromolecular complexes of proteins and lipids (triglycerides, cholesterol and phospholipids) in the circulation. They are classified
30 according to their relative densities: chylomicrons, chylomicron remnants (a metabolic product of chylomicrons), very low density lipoproteins ("VLDL"), intermediate density lipoproteins ("IDL"), a metabolic product of VLDL, low density lipoproteins ("LDL", an end
35 product of IDL) and high density lipoproteins ("HDL"). The protein components are called apolipoproteins. The major apolipoproteins are apoA-I, A-II, A-IV, B-100, B-48,

C-I, C-II, C-III, D, and E. ApoB-100 is present in VLDL, IDL and LDL, whereas apoE is present in chylomicron remnants, VLDL and IDL. High levels of circulating LDL and β -VLDL in blood in particular have been associated
5 with increased risk of cardiovascular heart disease.

ApoB-100 and apoE are ligands for the LDL receptor. Deficiency of the LDL receptor is a cause of familial hypercholesterolemia, an autosomal dominantly heritable disease which results in markedly elevated blood
10 plasma cholesterol levels, and often premature death due to atherosclerosis and resulting myocardial infarction. The administration of a low density lipoprotein receptor gene to attempt to treat familial hypercholesterolemia is discussed in Wilson et al., Human Gene Therapy, 3(2) 179-
15 222 (1992).

Summary of the Invention

This invention features methods of treating diseases or conditions, characterized by elevated serum lipoprotein levels by elevating levels of a VLDL receptor
20 in an animal, e.g., a human. Such receptors aid in removal of circulating VLDL and related lipoproteins, e.g., from the bloodstream, and thus decrease the risk of developing coronary diseases or conditions or decrease the severity of such diseases or conditions. Clones of human
25 and mouse VLDL receptor which can be used in the invention are also provided.

By "elevated" is meant a serum lipoprotein level above that recognized as within the normal range of levels. "Treating" means lowering the serum lipoprotein
30 level from an abnormally elevated level closer to a normal range of levels, or that the detrimental health effects of an abnormally elevated level of lipoproteins may be diminished or abolished. Examples of diseases or conditions characterized by elevated serum lipoprotein
35 levels are hyperlipidemia, atherosclerosis and hypercholesterolemia. These are only meant as examples

and are not meant to be limiting in any way. In addition, the methods of the invention can be used prophylactically, that is, even before an elevated level of various lipoproteins is evident. Thus, the invention has utility
5 in prevention of diseases or conditions to which an individual may be prone.

The VLDL receptor may be expressed only in a specific cell, such as a liver cell (hepatocyte), in which case "elevated" is relative to the normal range of VLDL
10 receptor typically expressed in such liver cells of a particular species or individual within that species. Alternatively or concurrently, the VLDL receptor can be expressed in the blood circulation or blood stream of an animal and in that case "elevated" is relative to the
15 normal range of VLDL receptors typically expressed in the blood stream of a particular species or individual within that species.

The term "elevating" means that VLDL receptor levels above those normally found in such an animal will
20 result from the administration of a VLDL receptor to an animal, or administration of nucleic acid vectors encoding a VLDL receptor through the expression of a nucleic acid sequence contained in the vector. The level of VLDL receptor normally found in any particular animal might be
25 zero.

In a preferred embodiment, an isolated nucleic acid encoding a VLDL receptor, e.g., a human or mouse VLDL receptor, is used to elevate the level of such a receptor within an animal or a cell. Such isolated nucleic acid
30 sequences include a cDNA, genomic DNA clone, RNA or an mRNA species which encode a sequence of a VLDL receptor obtained from a human or mouse and exhibiting some or all of the functional characteristics associated with such a VLDL receptor. Further, any such nucleic acid sequence
35 which encodes a portion of a VLDL receptor which exhibits the functional characteristics of a VLDL receptor as defined herein are within the preferred embodiment. These

functional characteristics of a VLDL receptor include but are not limited to the receptors use of apoE as a ligand and its specifically and competeably binding to and internalization, within a cell membrane in which the
5 receptor resides, of the apoE-containing lipoproteins, VLDL, IDL and β -VLDL, but not LDL.

A functional VLDL receptor may encompass any part of the VLDL receptor, alone or as part of a fusion protein, e.g., a VLDL receptor linked through a chemical
10 bond to a part or whole of another protein, so long as it functions as defined above.

More preferably the VLDL receptor portion of the fusion protein is able to cause specific removal of VLDL from the blood stream. Generally, such nucleic acid
15 encoding the VLDL receptor will have homology to Sequence ID Nos. 1 or 2, corresponding to human and mouse VLDL receptor nucleic acid sequences, respectively (Sequence ID No. 3 sets forth the human VLDL receptor amino acid sequence encoded by Sequence ID No. 1; Sequence ID No. 4
20 sets forth the mouse VLDL receptor amino acid sequence encoded by Sequence ID No. 2). That is it will have at least about 70% sequence identity along the length of the nucleic acid, preferably at least 80%, 90% or even 100% identity for at least 100, 200 or all nucleotide bases.
25 Such nucleic acid is thus distinct from that encoding an LDL receptor. In a preferred embodiment, the isolated nucleic acid sequence encodes a human or mouse VLDL receptor including additions, deletions or modifications to some or all of the sequence of the nucleic acid. That
30 is, the nucleic acid sequences may be altered at its 5' end 3' end, or at any point intermediate the 5' or 3' ends of the sequence.

By "modification" is meant that nucleic acid base analogues as are known in the art may be present, or
35 that one base, for example adenine may be substituted for another base, for example, guanine; the phosphodiester linkage may be modified as is known in the art, for

example by substitution of a thioester linkage; or the sugar moiety of the nucleic acid may be modified as is known in the art, for example, substitution of 2'-deoxyribose with 2', 3'-ribose or substitution of 2',3'-ribose with 2'-deoxyribose. These modifications may be made to one or more bases in the nucleic acid sequence. Modifications also include changes which, for example, stabilize the nucleic acid, but do not effect the function of the VLDL receptor (as can be determined by routine testing). Additionally, protein sequences comprising less than a whole VLDL receptor but which are nevertheless functional, may be mapped by mutational analysis or various clones may be created and the activity of proteins expressed from such clones assayed or other routine testing as is known in the art may be utilized.

In another preferred embodiment, the present invention includes a nucleic acid sequence, other than the sequence set forth as Sequence ID Nos. 1 or 2 but which will specifically hybridize to a segment of the nucleic acid sequence of the human or mouse VLDL receptor. This includes nucleic acid sequences which hybridize to any segment of the human or mouse VLDL receptor in a manner which is indicative of specific binding as opposed to non-specific background binding under conditions of stringency which would decrease non-specific binding, but would not be considered highly stringent. It does not include LDL receptor encoding nucleic acid sequences. In a preferred embodiment the invention includes a nucleic acid sequence other than the sequence set forth as Sequence ID Nos. 1 or 2 wherein the sequence will only hybridize to a segment of the nucleic acid sequence of the human or mouse VLDL receptor under highly stringent conditions. By "highly stringent conditions" is meant that non-specific hybridization would be expected to occur at a very low rate, e.g., hybridization would not be expected if there is more than about one nucleic acid base mismatch per 20.

nucleotide bases of human or mouse VLDL receptor nucleic acid sequence.

In another preferred embodiment, a nucleic acid sequence encoding a VLDL receptor is provided within a vector. The term "vector" as used herein refers to a nucleic acid, e.g., DNA derived from a plasmid, cosmid, phagemid or bacteriophage, into which fragments of nucleic acid may be inserted or cloned. The vector can contain one or more unique restriction sites for this purpose, and may be capable of autonomous replication in a defined host or organism such that the cloned sequence is reproduced. The vector molecule can confer some well-defined phenotype on the host organism which is either selectable or readily detected. Some components of a vector may be a DNA molecule further incorporating a DNA sequence encoding a therapeutic or desired product, and regulatory elements for transcription, translation, RNA stability and replication. A viral vector in this sense is one that contains a portion of a viral genome, e.g., a packaging signal, and is not merely DNA or a located gene within a viral article. The term "VLDL receptor vector" is synonymous with the above-recited definition.

In a preferred embodiment, a vector comprising nucleic acid encodes a VLDL receptor, wherein the VLDL receptor vector is adapted to cause expression of a VLDL receptor. Expression includes the efficient transcription of an inserted gene or nucleic acid sequence within the vector. Expression products may be proteins, polypeptides or RNA. By "expression of a VLDL receptor" is meant that a complete or functional partial VLDL receptor protein is produced from the vector containing the nucleic acid encoding a VLDL receptor.

In another preferred embodiment, a vector having nucleic acid sequences encoding a VLDL receptor is provided in which the nucleic acid sequence is expressed only in specific tissue. That is, a complete or partial functional VLDL receptor is produced from the vector

containing the nucleic acid encoding a VLDL receptor only in one or more predetermined, desired tissues. For example, muscle only, or liver only, or muscle and liver only.

5 In a preferred embodiment, a vector for the expression of a VLDL receptor nucleic acid sequence has a tissue-specific promoter, a VLDL receptor encoding nucleic acid sequence, and a post-transcriptional processing control sequence. The term "tissue-specific promoter" means that the promoter will allow transcription of RNA from the vector primarily only in a specific tissue in which the promoter is activated. For example, muscle cell specific promoters will only allow transcription in muscle cells. However, even with tissue-specific promoters some low level (about 10% or less than that observed in the desired tissue) expression might occur in other cell types. The promoter would still be defined as tissue specific. Methods of achieving tissue-specific gene expression as set forth in International Publication No. WO 93/09236, filed November 3, 1992 and published May 13, 1993; International Application No. PCT/US93/03993, filed April 28, 1993; International Application No. PCT/US93/03985, filed April 28, 1993; and U.S. patent application entitled "Specific Expression Vectors and Methods of Use", filed November 1, 1993 and U.S. patent application entitled "Keratin K1 Expression Vectors and Methods of Use"; all (including drawings) hereby incorporated by reference herein. By "post-transcriptional processing control sequence" is meant, for example, sequences which control intron deletion and exon splicing, polyadenylation or other modifications affecting RNA stability or RNA transport to cellular locations.

In all of the preceding vectors set forth above, a further aspect of the invention is that the nucleic acid sequence contained in the vector may include additions, deletions or modifications to some or all of the sequence of the nucleic acid, as defined above.

Yet an additional preferred embodiment, comprises a cell stably transfected with a VLDL receptor vector. The term "transfected" as used herein refers to a cell having undergone the process of introduction of
5 nucleic acid or a nucleic acid vector into a cell. Various methods of transfecting a cell are possible including microinjection, CaPO_4 precipitation, lipofection (liposome fusion), electroporation and use of a gene gun. The term "stable" as used herein refers to the
10 introduction of a gene into the chromosome of the targeted cell where it integrates and becomes a permanent component of the genetic material in that cell. An episomal transfection is a variant of stable transfection in which the introduced gene is not incorporated in the host cell
15 chromosomes but rather is replicated as an extrachromosomal element. This can lead to apparently stable transfection of the characteristics of a cell.

A cell may be co-transfected with a vector containing a selectable marker. This selectable marker is
20 used to select those cells which have become transfected. Types of selectable markers which may be used are well known to those of ordinary skill in the art.

In another preferred embodiment, there is provided a transfected cell wherein the VLDL receptor is
25 expressed as a cell surface protein. By "cell surface protein" is meant a protein which wholly or partially spans the cell membrane, and which is exposed on the surface of the cell.

In still another preferred embodiment, there is
30 provided a transfected cell wherein a VLDL receptor is expressed as a secreted protein. By "secreted protein" is meant a protein which is not associated with the cell membrane, but rather is intracellularly processed for secretion into the extracellular environment or other
35 cellular compartment.

Alternatively, a transfected cell containing a VLDL receptor vector may only be transiently transfected,

resulting in transient expression of a VLDL receptor. The term "transient" as used herein relates to the introduction of a gene into a cell to express a VLDL receptor, where the introduced gene is not integrated into the host cell genome and is accordingly eliminated from the cell over a period of time. Transient expression relates to the expression of a gene product during a period of transient transfection.

In yet a further preferred embodiment, there is provided a cell stably transformed with a VLDL receptor vector. The term "transformed" as used herein refers to a process or mechanism of inducing transient or permanent changes in the characteristics (expressed phenotype) of a cell by the mechanism of gene transfer whereby DNA or RNA is introduced into a cell in a form where it expresses a specific gene product or alters the expression or effect of endogenous gene products. The term "stable" as used herein refers to the introduction of gene(s) into the chromosome of the targeted cell where it integrates and becomes a permanent component of the genetic material in that cell. Gene expression after stable transformation can permanently alter the characteristics of the cell leading to stable transformation. An episomal transformation is a variant of stable transformation in which the introduced gene is not incorporated in the host cell chromosomes but rather is replicated as an extrachromosomal element. This can lead to apparently stable transformation of the characteristics of a cell.

Cells may be co-transformed with a vector containing a selectable marker. This selectable marker is used to select those cells which have become transformed. Types of selectable markers which may be used are well known to those of ordinary skill in the art.

The embodiments and definitions set forth above with respect to transfected cells, relating to cell surface proteins and secreted proteins, are equally

applicable to VLDL receptor expressed in stably transformed cells.

A cell transformed with a VLDL receptor vector may only be transiently transformed, resulting in transient expression of VLDL receptors. The term "transient" as used in transiently transformed is identical to that set forth with respect to transfected cells.

An additional preferred embodiment, provides for a transgenic animal containing a VLDL receptor vector. By "transgenic animal" is meant an animal whose genome contains an additional copy or copies of the gene from the same species or it contains the gene or genes of another species, such as a gene encoding a VLDL receptor introduced by genetic manipulation or cloning techniques, as described herein and as known in the art. The transgenic animal can include the resulting animal in which the vector has been inserted into the embryo from which the animal developed or any progeny of that animal. The term "progeny" as used herein includes direct progeny of the transgenic animal as well as any progeny of succeeding progeny. Thus, one skilled in the art will readily recognize that if two different transgenic animals have been made each utilizing a different gene or genes and they are mated, the possibility exists that some of the resulting progeny will contain two or more introduced genes. One skilled in the art will readily recognize that by controlling the matings, transgenic animals containing multiple introduced genes can be made.

A further preferred embodiment comprises a ligand capable of specifically binding to a VLDL receptor wherein the ligand has associated with it a detectable label. A "ligand" is a molecule or an assemblage of molecules capable of specifically binding to a VLDL receptor. The term "specifically binding" means that a labelled ligand bound to a VLDL receptor can be competeably displaced from the VLDL receptor by the

addition of unlabelled ligand, as is known in the art. An example of a ligand would be a monoclonal antibody specific for the VLDL receptor. The term "associated with" means that the ligand is either covalently or ionically or hydrophobically or otherwise linked to the detectable label, such that wherever the detectable label is found the ligand will also be found. A "detectable label" is a molecule, for example, an enzyme, a proenzyme, a fluorescent or bioluminescent or radioactive molecule which will give rise to a signal including but not limited to: Production of luminescent or fluorescent products, alteration of luminescence, chemiluminescence or its alteration, light absorbent products, pH changes, magnetic resonance imaging changes, alteration in the absorption or emission of electromagnetic radiation, gravimetric, volumetric, or electrochemical changes, or precipitation or agglutination.

In another preferred embodiment, a method of introducing a continuous supply of VLDL receptor into an animal or a tissue culture by administering an effective amount of a vector is provided. By "continuous" is meant that the VLDL receptor is constitutively expressed without the need for the addition of an exogenously administered activating compound to initiate expression. The term "effective amount" means an amount sufficient to give expression of some amount of VLDL receptor in the muscle or tissue culture. This amount may be as low as expression of about one VLDL receptor per thousand cells.

In another preferred embodiment, a method of gene replacement is set forth. "Gene replacement" as used herein means supplying a nucleic acid sequence which is capable of being expressed in vivo in an animal and thereby providing or augmenting the function of an endogenous gene which is missing or defective in the animal.

In another preferred embodiment, there is provided a method of introducing into an animal a VLDL

receptor vector containing a VLDL receptor of another species and capable of expressing in whole or in part or in modified form this other species VLDL receptor. This transgenic animal is useful in screening compounds for their pharmacological effects on lipoprotein metabolism comprising the steps of administering compounds to the transgenic animal and measuring lipoprotein metabolism in the transgenic animal. The term "administering" includes any of the methods of administration described below in the Detailed Description of the Invention section. The term "pharmacological effects" means that a compound increases or decreases the serum level of a particular lipoprotein by any mechanism, including, but not limited to, directly or indirectly decreasing lipoprotein synthesis, increasing lipoprotein uptake, excretion or conversion to another substance.

In another preferred embodiment, an *in vivo* method of administering a nucleic acid sequence is provided, as described below. In a further preferred embodiment, naked DNA may be administered. The term "naked DNA" means substantially pure DNA which is not associated with protein, lipid, carbohydrate or contained within a cell or an artificial delivery system such as a liposome. A tissue or cell may also be transduced with a VLDL receptor vector. The term "transduced or transduction" as used herein refers to the process of introducing a recombinant virus into a cell by infecting the cell with the virus particle. The virus may be administered substantially simultaneously, *i.e.*, the VLDL nucleic acid sequence and the virus may administered in the same composition or that the administration of one may follow the other by about up to one hour.

In an additional preferred embodiment a method of administering VLDL nucleic acid sequence through cell surface receptor mediated endocytosis is provided. That is, the biological process whereby cell surface receptors which have bound a ligand cluster together on the cell

surface followed by invagination of the cell membrane containing the clustered receptors and formation of an intercellular vesicle containing the receptor ligand complexes. A "cell surface receptor" is a specific chemical grouping on the surface of a cell to which a ligand can attach. Cell surface receptors which may be used in the present invention include the folate receptor, the biotin receptor, the lipoic acid receptor, the low density lipoprotein receptor, the asialoglycoprotein receptor, IgG antigenic sites, insulin-like growth factor type II/cation-independent mannose-6-phosphate receptor, calcitonin gene-related peptide receptor, insulin-like growth factor I receptor, nicotinic acetylcholine receptor, hepatocyte growth factor receptor, endothelin receptor, bile acid receptor. Further, incorporating DNA into macromolecular complexes that undergo endocytosis increases the range of cell types that will take up foreign genes from the extracellular space. Such complexes may include lipids, polylysine, viral particles, ligands for specific cell-surface receptors or nuclear proteins.

The term "DNA transporter" refers to a molecular complex which is capable of non-covalently binding to DNA and efficiently transporting the DNA through the cell membrane. Although not necessary, it is preferable that the transporter also transport the DNA through the nuclear membrane. The methods and material set forth in International Publication No. WO 93/18759, filed March 19, 1993 and published September 30, 1993 are hereby incorporated by reference.

In another preferred embodiment, a two-component system of administering a VLDL nucleic acid sequence is provided. The term "two-component system" means a system utilizing a packaging cell which produces a viral vector. In a preferred embodiment, a partial hepatectomy may be performed prior to administration of the packaging cell.

The term "hepatectomy" or "partial hepatectomy" is used as is commonly understood in the art.

In an additional preferred embodiment, a retroviral vector containing a modified retroviral envelope glycoprotein is provided. The term retroviral envelope glycoprotein is used as is commonly understood in the art.

In another preferred embodiment, a method of isolating additional animal lipoprotein receptor genes utilizing a probe or probes is provided. That is, genes with a nucleic acid sequence other than Sequence ID Nos. 1 or 2, which when expressed produce a functional lipoprotein receptor. Functional lipoprotein receptor is defined as above for the VLDL receptor, or is a receptor which will specifically bind a lipoprotein. The term "probe or probes" is used as is commonly understood in the art.

Another preferred embodiment provides for a method of enhancing the effect of administering a nucleic acid expression vector encoding a VLDL expression vector by also administering a nucleic acid expression vector encoding a lipoprotein lipase. The term "enhancing" means increasing the effect of administering a nucleic acid expression vector encoding a VLDL expression vector, whereby the amount of increased effect may be as small a difference as may be detected, utilizing methods known in the art. The term "lipoprotein lipase" is used as is commonly understood in the art. The term "administered substantially simultaneously" means that the nucleic acid expression vector encoding a VLDL receptor nucleic acid sequence and the expression vector encoding a lipoprotein lipase nucleic acid sequence may be administered in the same composition, or that the administration of one may follow the other by about up to one hour. The term "administered after some period of time" means that the nucleic acid expression vector encoding a VLDL receptor nucleic acid sequence and the expression vector encoding

a lipoprotein lipase nucleic acid sequence may administered such that one follows the other by more than one hour.

In another preferred embodiment, a method of
5 diagnostic imaging is provided. The term "diagnostic imaging" means the ability to perceive the tissue distribution of a VLDL receptor in a particular animal in vivo or a in a tissue ex vivo. The term "imageable compound" means a compound which generates a signal
10 detectable as a human perceivable visual signal, an electromagnetic signal, a radioactive signal or a signal detectable by magnetic resonance imaging, positron emission tomography or computerized axial tomography as is known in the art.

15 Therapeutic agents, such as a VLDL receptor vector and VLDL receptor protein that lower plasma VLDL will accomplish two important objectives: first, they will lower IDL and LDL, the metabolic products of VLDL, and total plasma cholesterol, and second, they will
20 simultaneously lower triglycerides. The lowering of IDL and LDL and total plasma cholesterol is highly desirable because of the known strong association between these lipid parameters and coronary heart disease. The lowering of triglyceride is also of benefit especially when it
25 occurs in the presence of atherogenic dyslipidemias which is a common occurrence. Use of the VLDL receptor vector and VLDL receptor protein should also effectively lower LDL in homozygous FH patients because VLDL is the precursor of LDL. Furthermore, the VLDL receptor offers
30 an important advantage over the LDL receptor. FH patients have either no LDL receptor or abnormal LDL receptor. With the expression of the normal LDL receptor, they will develop antibodies to the protein which will eventually interfere with the continued expression of the LDL
35 receptor and the effectiveness of treatment. The VLDL receptor, on the other hand, is normally present in multiple tissues in these patients. Therefore, the

induced overexpression of the VLDL receptor in tissues that normally produce it, or the induced expression of the receptor in an ectopic site such as the liver will not cause any untoward immunological response. This is a major advantage of the use of the VLDL receptor. Use of the VLDL receptor vector and VLDL receptor protein will decrease or eliminate the need for invasive surgical procedures, such as heart bypass surgery or balloon angioplasty.

Other and further objects, features and advantages will be apparent from the following description of the presently preferred embodiments in the invention.

Detailed Description of the Invention

The drawings will first briefly be described.

15 Drawings:

Figure 1 illustrates the nucleic acid sequence of a human VLDL receptor.

Figure 2 illustrates the nucleic acid sequence of a mouse VLDL receptor.

20 Figure 3 illustrates the amino acid sequence of a human VLDL receptor encoded by Sequence ID No. 1, utilizing the one letter code as is well known in the art.

Figure 4 illustrates the amino acid sequence of a mouse VLDL receptor encoded by Sequence ID No. 2, 25 utilizing the one letter code as is well known in the art.

VLDL Receptor

The amino acid sequences of the human and mouse VLDL receptors have been deduced from their respective cloned cDNAs which were isolated and sequenced. See, 30 Sequence ID Nos. 1 and 2. Each protein is predicted to contain 873 amino acid residues, including 27 residues in the signal peptide. Thus, the two proteins are identical in size. The cDNA nucleotide sequences and predicted amino acid sequences also show high homology between the 35 two species. (The cDNA for the rabbit VLDL receptor has

been cloned. Takahashi et al., Proc. Natl. Acad. Sci. USA, 89: 9252-9256, (1992)).

The N-terminal 27 amino acid sequence (residues -27 to -1) is hydrophobic in nature and constitutes the putative signal peptide. The mature human and mouse VLDL receptor protein contains three potential N-linked glycosylation sites (Asn-124, 737 and 754). Like the LDL receptor (Yamamoto et al., Cell 39: 27-38, 1984; Yamamoto et al., Science 232: 1230-1237, 1986), the human and mouse VLDL receptor can be divided into five domains. At the N-terminal region are 8-fold ~40 residue cysteine-rich repeats that are homologous to the ligand binding region of the LDL receptor which contains 7-fold repeat units (Esser et al., J. Biol. Chem. 263: 13282-13290, 1988; Russell et al., J. Biol. Chem. 264: 21682-21688, 1989). The next domain, which has homology to the epidermal growth factor precursor, spans 396 amino acids including three cysteine-rich repeats, designated A, B and C. This domain in the LDL receptor is thought to be important for the acid-dependent dissociation of the ligand from the receptor (Davis et al., Nature 326: 760-765, 1987). The next domain, the clustered O-linked sugar region, is well conserved among the known mammalian VLDL receptor sequences. The last two domains, the transmembrane domain and the cytoplasmic domain, are completely conserved with no amino acid change between human and mouse VLDL receptors. In the LDL receptor, there is a conserved tetrapeptide NPXY (Asn-Pro-X-Tyr) (wherein X is any amino acid) in the cytoplasmic domain which is required for clustering of the LDL receptor in coated pits (Chen et al., J. Biol. Chem. 265: 3116-3123, 1990). In the human, mouse and rabbit VLDL receptor, the tetrapeptide has the sequence NPVY (Asn-Pro-Val-Tyr). Overall, the VLDL receptor has evolved at a much slower rate than the LDL receptor.

The cloned human VLDL receptor cDNA probe was used to localize the VLDL receptor gene on chromosomal

spreads by fluorescence *in situ* hybridization. A hybridization signal was consistently observed on chromosome band 9p24. Thus, the VLDL receptor is on a chromosome different from the LDL receptor which is
5 located on chromosome 19p13 (Lindgren et al., Proc. Natl. Acad. Sci. USA 82: 8567-8571, 1985).

The VLDL receptor binds to apolipoprotein (apo) E-containing lipoproteins, including VLDL, intermediate density lipoprotein (IDL), and β -VLDL. It may also bind
10 to chylomicrons and chylomicron remnants which also contain apoE. Unlike an LDL receptor, a VLDL receptor will not competeably bind to and internalize LDL. As described above, a VLDL receptor encompasses any fragment of a VLDL receptor which exhibits functional properties of
15 a VLDL receptor as defined above.

VLDL are the precursors of IDL and LDL. Both IDL and LDL have been identified as important risk factors for atherosclerosis. Therefore, any therapeutic intervention that lowers IDL and LDL will reduce their
20 atherogenic potential. There is recent evidence that lowering serum cholesterol and LDL may actually cause regression of atheromatous lesions. Elevated triglycerides are positively correlated with risk for coronary heart disease. Much of this association may be
25 related to the fact that high triglycerides often occur in the presence of reduced high density lipoproteins (HDL). HDL is thought to be anti-atherogenic and low HDL predisposes one to atherosclerosis. Furthermore, high triglycerides are often associated with atherogenic forms
30 of LDL (e.g., in familial combined hyperlipidemia and diabetic dyslipidemia).

Therapeutic agents that lower plasma VLDL will accomplish two important objectives: first, they will lower IDL and LDL, the metabolic products of VLDL, and
35 total plasma cholesterol, and second, they will also lower triglyceride levels. The lowering of IDL and LDL and total plasma cholesterol is highly desirable because of

the known strong association between these lipid parameters and coronary heart disease. The lowering of triglyceride is also of benefit especially when it occurs in the presence of atherogenic dyslipidemias, a common
5 situation. In fact, therapeutic intervention in this situation is recommended by the National Cholesterol Education Program (NCEP) Expert Panel (Adult Treatment Panel II) (JAMA 269: 3015-3023, 1993).

It would be useful to control blood levels of β -
10 VLDL, VLDL and IDL through the use of exogenously administered VLDL receptor binding to these ligands, thereby decreasing the risk of cardiovascular disease and the resulting need for invasive surgical procedures directed at the heart.

15 Currently, there is a clinical protocol approved for the treatment of LDL receptor deficient homozygous FH patients by somatic gene therapy using the human LDL receptor gene (Wilson, Hum. Gene Ther. 3: 179-222, 1992). Use of the VLDL receptor should also effectively lower LDL
20 in homozygous FH patients because VLDL is the precursor of LDL. Furthermore, the VLDL receptor offers one important advantage over the LDL receptor. FH patients have either no LDL receptor or abnormal LDL receptor. With the expression of the normal LDL receptor, they will develop
25 antibodies to the protein which will eventually interfere with the continued expression of the LDL receptor and the effectiveness of treatment. The VLDL receptor, on the other hand, is normally present in multiple tissues in these patients. Therefore, the induced over-expression of
30 the VLDL receptor in tissues that normally produce it, or the induced expression of the receptor in an ectopic site such as the liver will not cause any untoward immunological response. This is a major advantage of the use of the VLDL receptor.

35 Administration

The nucleic acid sequence encoding VLDL receptor can be administered prophylactically, or to patients

having a disease or condition characterized by an elevated plasma lipoprotein level, e.g., by exogenous delivery of the nucleic acid sequence encoding VLDL receptor as naked DNA, DNA associated with specific carriers, or in a nucleic acid expression vector to a desired tissue by means of an appropriate delivery vehicle, e.g., a liposome, by use of iontophoresis, electroporation and other pharmacologically approved methods of delivery. Routes of administration may include intramuscular, intravenous, aerosol, oral (tablet or pill form), topical, systemic, ocular, as a suppository, intraperitoneal and/or intrathecal.

The specific delivery route of a VLDL receptor will depend on the use of the VLDL receptor.

Some methods of delivery that may be used include:

- a. encapsulation in liposomes,
- b. transduction by retroviral vectors,
- c. localization to nuclear compartment utilizing nuclear targeting site found on most nuclear proteins,
- d. transfection of cells ex vivo with subsequent reimplantation or administration of the transfected cells,
- e. a DNA transporter system.

At least three types of delivery strategies are useful in the present invention, including: Injection of naked VLDL receptor DNA or charge modified naked VLDL receptor DNA, particle carrier drug delivery vehicles which are also suitable for delivery of VLDL receptor proteins, and retroviral expression vectors. Unmodified nucleic acid sequence encoding VLDL receptors, like most small molecules, are taken up by cells, albeit slowly. To enhance cellular uptake, the nucleic acid sequence encoding VLDL receptor may be modified in ways which reduce its charge but will maintain the expression of specific functional groups in the final translation

product. This results in a molecule which is able to diffuse across the cell membrane, thus removing the permeability barrier.

Chemical modifications of the phosphate backbone will reduce the negative charge allowing free diffusion across the membrane. This principle has been successfully demonstrated for antisense DNA technology which shows that this is a feasible approach. In the body, maintenance of an external concentration will be necessary to drive the diffusion of the modified nucleic acid sequence encoding the VLDL receptor into the cells of the tissue. Administration routes which allow the tissue to be exposed to a transient high concentration of the nucleic acid sequence encoding the VLDL receptor, which is slowly dissipated by systemic adsorption are preferred. Intravenous administration with a drug carrier designed to increase the circulation half-life of the nucleic acid sequence encoding the VLDL receptor or VLDL receptor proteins can be used. The size and composition of the drug carrier restricts rapid clearance from the blood stream. The carrier, made to accumulate at the desired site of transfer, can protect the nucleic acid sequence encoding the VLDL receptor from degradative processes.

Drug delivery vehicles are effective for both systemic and topical administration. They can be designed to serve as a slow release reservoir, or to deliver their contents directly to the target cell. An advantage of using direct delivery drug vehicles is that multiple molecules are delivered per uptake. Such vehicles have been shown to increase the circulation half-life of drugs which would otherwise be rapidly cleared from the blood stream. Some examples of such specialized drug delivery vehicles which fall into this category are liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres.

From this category of delivery systems, liposomes are preferred. Liposomes increase intracellular

stability, increase uptake efficiency and improve biological activity.

Liposomes are hollow spherical vesicles composed of lipids arranged in a similar fashion as those lipids which make up the cell membrane. They have an internal aqueous space for entrapping water soluble compounds and range in size from 0.05 to several microns in diameter. Several studies have shown that liposomes can deliver nucleic acids to cells and that the nucleic acid remains biologically active.

For example, a liposome delivery vehicle originally designed as a research tool, Lipofectin, has been shown to deliver intact mRNA molecules to cells yielding production of the corresponding protein.

Liposomes offer several advantages: They are non-toxic and biodegradable in composition; they display long circulation half-lives; and recognition molecules can be readily attached to their surface for targeting to tissues. Finally, cost effective manufacture of liposome-based pharmaceuticals, either in a liquid suspension or lyophilized product, has demonstrated the viability of this technology as an acceptable drug delivery system.

Other controlled release drug delivery systems, such as nanoparticles and hydrogels may be potential delivery vehicles for a nucleic acid sequence encoding a VLDL receptor. These carriers have been developed for chemotherapeutic agents and protein-based pharmaceuticals (such as VLDL receptor proteins), and consequently, can be adapted for nucleic acid delivery.

Chemical modification of the nucleic acid sequence encoding a VLDL receptor to neutralize negative charge may be all that is required for penetration. However, in the event that charge neutralization is insufficient, the nucleic acid sequence encoding a VLDL receptor can be co-formulated with permeability enhancers, such as Azone or oleic acid, in a liposome. The liposomes can either represent a slow release presentation vehicle

in which the modified nucleic acid sequence encoding a VLDL receptor and permeability enhancer transfer from the liposome into the targeted cell, or the liposome phospholipids can participate directly with the modified nucleic acid sequence encoding a VLDL receptor and permeability enhancer can participate directly with the modified nucleic acid encoding a VLDL receptor and permeability enhancer facilitating cellular delivery. In some cases, both the nucleic acid encoding a VLDL receptor and permeability enhancer can be formulated into a suppository formulation for slow release.

The nucleic acid sequence encoding a VLDL receptor or a VLDL receptor protein may also be systemically administered. Systemic absorption refers to the accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes which lead to systemic absorption include: intravenous, intramuscular, subcutaneous, intraperitoneal, intranasal, intrathecal and ophthalmic. A gene gun may also be utilized. Administration of DNA-coated microprojectiles by a gene gun requires instrumentation but is as simple as direct injection of DNA. A construct bearing the gene of interest is precipitated onto the surface of microscopic metal beads. The microprojectiles are accelerated with a shock wave or expanding helium gas, and penetrate tissues to a depth of several cell layers. This approach permits the delivery of foreign genes to the skin of anesthetized animals. This method of administration achieves expression of transgenes at high levels for several days and at detectable levels for several weeks. Each of these administration routes exposes the nucleic acid sequence encoding a VLDL receptor to an accessible targeted tissue. Subcutaneous administration drains into a localized lymph node which proceeds through the lymphatic network into the circulation. The rate of entry into the circulation has been shown to be a function of molecular weight or size.

The use of a liposome or other drug carrier localizes the nucleic acid sequence encoding VLDL receptor at the lymph node. The nucleic acid sequence encoding VLDL receptor can be modified to diffuse into the cell, or the liposome
5 can directly participate in the delivery of either the unmodified or modified nucleic acid sequence encoding VLDL receptor to the cell.

Liposomes injected intravenously show accumulation in the liver, lung and spleen. The
10 composition and size can be adjusted so that this accumulation represents 30% to 40% of the injected dose. The remaining dose circulates in the blood stream for up to 24 hours.

The chosen method of delivery should result in
15 cytoplasmic accumulation and molecules should have some nuclease-resistance for optimal dosing. Nuclear delivery may also be used. Most preferred delivery methods include liposomes (10-400 nm), hydrogels, controlled-release polymers, microinjection or electroporation (for ex vivo
20 treatments) and other pharmaceutically applicable vehicles. The dosage will depend upon the disease indication and the route of administration but should be between 1-1000 µg/kg of body weight/day. The duration of treatment will extend through the course of the disease
25 symptoms, possibly continuously. The number of doses will depend upon disease delivery vehicle and efficacy data from clinical trials.

Another method of administration involves the use of a DNA transporter system for inserting specific DNA
30 into a cell. The DNA transporter system comprises a plurality of a first DNA binding complex, said complex including a first binding molecule capable of non-covalently binding to DNA, said first binding molecule covalently linked to a surface ligand, said surface ligand
35 capable of binding to a cell surface receptor; a plurality of a second DNA binding complex, said complex including a second binding molecule capable of non-covalently binding

to DNA, said second binding molecule covalently linked to a nuclear ligand, said nuclear ligand capable of recognizing and transporting a transporter system through a nuclear membrane; wherein said plurality of first and
5 second DNA binding complexes are capable of simultaneously, non-covalently binding to a specific DNA.

Additionally, a plurality of a third DNA binding complex may be used, said complex includes a third binding molecule capable of non-covalently binding to DNA,
10 said third binding molecule covalently linked to a virus; wherein said plurality of third DNA binding complexes are capable of simultaneously, non-covalently binding to a specific DNA.

The first binding molecule, the second binding
15 molecule and third binding molecule can each be selected from the group consisting of spermine, spermine derivative, histones, cationic peptides and polylysine. Spermine derivative refers to analogues and derivatives of spermine and include compounds as set forth in
20 International Publication No. WO 93/18759, filed March 19, 1993 and published September 30, 1993 hereby incorporated by reference.

Establishment of therapeutic levels of nucleic acid sequence encoding VLDL receptor within the cell is
25 dependent upon the rates of uptake and degradation. Decreasing the degree of degradation will prolong the intracellular half-life of the VLDL receptor gene. Descriptions of useful systems are provided in the art cited above, all of which is hereby incorporated by
30 reference.

A VLDL receptor nucleic acid sequence may be administered utilizing an ex vivo approach whereby cells are removed from an animal, transduced with the VLDL receptor nucleic acid sequence and reimplanted into the
35 animal. The liver can be accessed by an ex vivo approach by removing hepatocytes from an animal, transducing the hepatocytes *in vitro* with the VLDL receptor nucleic acid

sequence and reimplanting them into the animal (e.g., as described for rabbits by Chowdhury et al, Science 254: 1802-1805, 1991, or in humans by Wilson, Hum. Gene Ther. 3: 179-222, 1992) incorporated herein by reference.

5 The VLDL receptor nucleic acid sequence may be administered utilizing an *in vivo* approach whereby the gene will be administered directly to an animal by intravenous injection, intramuscular injection, or by catheterization and direct delivery of the gene via the
10 blood vessels supplying the target organ. Since the VLDL receptor is normally expressed in multiple tissues and organs including heart, skeletal muscle, adipose tissues, spleen, lung, brain, kidney, testis, adrenal, small intestine, and other tissues, any of these tissues can be
15 target organs. Among these tissues, skeletal muscle is one tissue that is readily accessible by intramuscular injection or intravenous injection. Expression will be achieved using a skeletal muscle-specific promoter for the nucleic acid sequence encoding VLDL receptor.

20 Normally there is little expression of the VLDL receptor in the liver. This organ is, however, also a good target organ for expression because the liver clears large volumes of blood and is able to metabolize the apoE-containing lipoproteins that bind to the VLDL receptor and
25 become internalized in this organ. The liver can also be accessed by an *in vivo* approach by administration of the nucleic acid sequence encoding VLDL receptor intravenously, intraportally (via the portal vein) or intra-arterially into the hepatic artery.

30 Many nonviral techniques for the delivery of a VLDL receptor nucleic acid sequence into a cell can be used, including direct naked DNA uptake (e.g., Wolff et al., Science 247: 1465-1468, 1990), receptor-mediated DNA uptake, e.g., using DNA coupled to asialoorosomucoid which
35 is taken up by the asialoglycoprotein receptor in the liver (Wu and Wu, J. Biol. Chem. 262: 4429-4432, 1987; Wu et al., J. Biol. Chem. 266: 14338-14342, 1991), and

liposome-mediated delivery (e.g., Kaneda et al., Expt. Cell Res. 173: 56-69, 1987; Kaneda et al., Science 243: 375-378, 1989; Zhu et al., Science 261: 209-211, 1993). Many of these physical methods can be combined with one
5 another and with viral techniques; enhancement of receptor-mediated DNA uptake can be effected, for example, by combining its use with adenovirus (Curiel et al., Proc. Natl. Acad. Sci. USA 88: 8850-8854, 1991; Cristiano et al., Proc. Natl. Acad. Sci. USA 90: 2122-2126, 1993).

10 Vectors

The construction of expression vectors encoding a VLDL nucleic acid sequence encoding a VLDL receptor in whole or in part or in modified form will be performed utilizing standard techniques known to those of ordinary
15 skill in the art as set forth in, for example, Maniatis, Fritsch and Sambrook, Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982. The nucleic acid sequence encoding a VLDL receptor or a functional part thereof will be
20 inserted at one end of a promoter, typically but not necessarily the 3' end, the promoter capable of directing appropriate transcription of the VLDL nucleic acid sequence. The promoter used can be any that gives good expression of a VLDL receptor, these include the
25 retroviral long terminal repeat (LTR) promoter, RSV-LTR, MuV-LTR, promoters from cytomegalovirus, apolipoprotein A-I, albumin (together with its enhancer), transthyretin, transferrin, skeletal muscle actin, metallothionein, or a myogenic specific promoter selected from a group
30 consisting of skeletal alpha actin gene promoter, first myosin light chain 1 promoter, myosin heavy chain promoter, tropinin T promoter, muscle creatinine kinase promoter/enhancer, cytomegalovirus promoter, RSV promoter and Rous Sarcoma virus LTR. In the preferred embodiment
35 the skeletal alpha actin promoter is used. Other promoters as are known in the art may also be used. Also, specific embodiments may include the addition of

regulatory promoter elements to regulate the expression of any specific nucleic acid sequence in myogenic tissue. In the preferred embodiment, Vitamin D is used to regulate expression. One skilled in the art will recognize that the selection of the promoter will depend on the vector, the VLDL receptor nucleic acid sequence utilized and the desired biological effect. One skilled in the art will also recognize that in the selection of a promoter the parameters can include: achieving sufficiently high levels of gene expression to achieve a physiological effect; maintaining a critical steady state of gene expression; achieving temporal regulation of gene expression; achieving tissue-specific expression; achieving pharmacological, endocrine, paracrine or autocrine regulation of gene expression; and preventing inappropriate or undesirable levels of expression. Any given set of selection requirements will depend on the conditions, but can be readily determined once the specific requirements are determined.

Genomic sequences comprising an intron or introns and in certain embodiments including regulatory sequences for transcription or RNA stability may be included. These may include 3' untranslated sequences possibly including regulatory sequences for RNA stability. A polyadenylation signal from genes such as growth hormone or SV40 or others as are known in the art will be ligated to one end of the nucleic acid sequence, typically the 3' end of the nucleic acid sequence.

In the case of a retroviral vector the elements include two long terminal repeat sequences, the Ψ (packaging) sequence which may extend into the gag region of the retrovirus and may be modified to eliminate splice signals or translation initiation sites, a promoter capable of producing appropriately regulated transcription of VLDL receptor nucleic acid sequences. In alternate embodiments the retroviral vector can include a selectable marker for chemical, pharmacological, or fluorescent

elimination of non-transduced cells and/or other retroviral sequences required for integrity and function of the retroviral vector.

A number of viral vectors can be used to deliver
5 a VLDL receptor nucleic acid sequence, including papovaviruses, adenovirus, vaccinia virus, adeno-associated virus, herpesviruses, retroviruses of avian, murine, and human origin and other viruses as are known in the art (reviewed by Morgan and Anderson, Ann. Rev.
10 Biochem. 62: 191-217, 1993 incorporated herein by reference.) Retroviral vectors can be used for transducing the VLDL receptor vector into liver cells or muscle. The advantage of retrovirus as a delivery system is the ability of the virus to integrate into the host
15 cell chromosomes (reviewed by A.D. Miller, Hum. Gene Ther. 1: 5-14, 1990). The VLDL receptor vector can be delivered by retroviral-mediated gene transfer, a two-component system consisting of the packaging cell and the viral vector. The VLDL receptor nucleic acid sequence can be
20 inserted into the retroviral vector by molecular cloning (e.g., as described by Wilson, Hum. Gene Ther. 3: 179-222, 1992). The virus particle assembled by the producer cell line (i.e., a packaging cell line containing the VLDL receptor-containing retroviral vector) will be used to
25 transfer the VLDL receptor nucleic acid sequence to a target organ or tissue such as liver cells in vivo (following partial hepatectomy because only dividing cells take up retroviral vectors), isolated hepatocytes in vitro or skeletal muscle in vivo. The virus particle will bind
30 to the cell and deliver the VLDL receptor nucleic acid sequence which is integrated into the host genome and result in stable long-term expression of the VLDL receptor.

Two major limitations to the use of retroviral
35 vectors are the restricted host-cell range and the inability to obtain high-titer virus. These limitations have been overcome by Burns et al., Proc. Natl. Acad. Sci.

USA 90: 8033-8037, 1993. They replaced the retroviral envelope glycoprotein with the G glycoprotein of vesicular stomatitis virus. Such vectors can be produced in high titer ($>10^9$ colony-forming units/ml) and can infect diverse cell types. Partial hepatectomy may not be necessary for liver expression using such vectors. The nucleic acid sequence encoding VLDL receptor can be delivered by using this or a similarly designed vector *in vivo* by intravenous administration.

10 The other viral vector delivery system that will be used is the adenovirus system. The VLDL receptor nucleic acid sequence can be used to replace the E1 region of the adenovirus using the method described by Graham and Prevec (Methods Molec. Biol., Vol. 7, E.J. Murray, ed., Humana Press, NJ, pp. 109-128, 1991) using recombination in 293 cells incorporated herein by reference. The replication-defective VLDL receptor nucleic acid sequence/adenovirus can be injected intravenously, intramuscularly, intraportally or intra-arterially (hepatic artery). To date, adenovirus-mediated expression vectors generally direct the transient expression of the therapeutic gene. Improvements and refinements in vector structure and design may lead to diminished immunogenicity and allow the vector to be administered repeatedly. Other modifications may result in the ability of the VLDL receptor nucleic acid sequence to be integrated in the host chromosomes allowing for stable expression.

25 Other viral vector delivery systems as are known in the art will also be used for the targeted transfer of the VLDL receptor nucleic acid sequence.

30 The following examples are offered by way of illustration and are not intended to limit the invention in any manner.

Example 1: Methods of Augmenting Levels of Expression
of Human or Mouse VLDL Receptor Vector

Normally, the VLDL receptor is expressed at a high level in skeletal muscle, although the exact level of expression has not been defined. For a therapeutic effect using muscle expression, it will be necessary to increase VLDL expression by about 5% or more. The persistent over-expression of the VLDL receptor in muscle by this amount should lead to a substantial lowering of plasma VLDL, IDL and LDL.

Liver normally does not express detectable amounts of VLDL receptor. Therefore, the induced expression of low level of VLDL receptor should have a substantial effect on plasma lipoproteins. The minimal level aimed at is an average expression of one molecule per cell (i.e., 1000 receptors per cell if 0.1% of hepatocytes show expression, 100 receptors per cell if 1% express it and so on). For patients with more severe elevation of LDL cholesterol, e.g., levels of about 200 mg/dL to 250 mg/dL or higher, a higher level of expression will be targeted, e.g., aiming at 10-1000 molecules per cell. The relatively high level of expression will be a function of the nucleic acid sequence encoding VLDL receptor construct (e.g., different promoters will have different activities) and the delivery method (e.g., naked DNA delivery, liposome delivery, receptor-mediated delivery, retrovirus-mediated delivery and adenovirus-mediated delivery will have different efficiencies, and in vivo versus ex vivo delivery will also produce different results) which can be experimented on and optimized. The level of expression will be determined at the RNA level by RNA blotting or S1 protection assay, and at the protein level by immunoblot analysis and by receptor-binding assay by the method of Goldstein et al., Methods Enzymol. 98: 241-260, 1983.

Example 2: Methods of Enhancing VLDL Receptor Activity by
Expression of Lipoprotein Lipase (LPL)

VLDL receptor and LPL are expressed in similar tissues, e.g., heart, skeletal muscle and adipose tissue. LPL has been found to play an important role in the receptor-mediated uptake of various lipoproteins (Eisenberg et al., J. Clin. Invest. 90: 2013-2021) via LDL receptor related protein ("LRP") (Chappell et al., J. Biol. Chem. 267: 25764-25767, 1992; Beisiegel et al., Proc. Natl. Acad. Sci. USA 88: 8342-8346, 1991), and LDL receptor (Mulder et al., J. Biol. Chem. 268: 9369-9375, 1993). It also may be involved in the non-receptor mediated uptake of lipoproteins (Mulder et al., J. Biol. Chem. 268: 9369-9375, 1993; Rumsey et al., J. Clin. Invest. 90: 1504-1512, 1992; Williams et al., J. Biol. Chem. 267: 13284-13292, 1992). The co-expression of LPL in the same tissues that express the VLDL receptor will enhance the activity of the latter. To accomplish this, an LPL gene vector will be delivered using a similar design as the VLDL gene vector. The two vectors can be delivered simultaneously, or they can be delivered consecutively with a varying period in between. It is expected that the activity of the VLDL receptor will be markedly enhanced by this method of co-expression.

Example 3: Human or Mouse VLDL Receptor Variants

The human or mouse VLDL receptor may be used without modification for gene therapy. However, variants of the human or mouse nucleic acid sequence encoding VLDL receptor generated by site-specific mutagenesis and having the following properties, such as; increased affinity for the ligand, recognition of apoB-containing lipoproteins in addition to apoE-containing lipoproteins, or usefulness for screening for pharmaceutical agents that bind to the VLDL receptor and modulate its activity (see, Example 5 below) will also be useful. Selection from a wide variety of methods for site-directed mutagenesis for modifying the

VLDL receptor, including the methods of Taylor et al., Nucleic Acids Res. 13: 8765-8785, 1985, and of Deng and Nickoloff, Anal. Biochem. 200: 81-88, 1992, incorporated herein by reference, may be used.

5 Example 4: Determination of Serum Chemistry Values for
Patients Undergoing VLDL Gene Therapy

A large number of serum chemistry values will be obtained as for all patients with hyperlipidemia who are at risk for accelerated atherosclerosis. The following
10 values are specifically measured with respect to VLDL receptor gene therapy: total serum cholesterol, triglyceride, LDL-cholesterol, HDL, apoA-I, apoE (level and isoform), apoB, and lipoprotein (a). The aim of VLDL gene therapy is to reduce total serum cholesterol (and
15 triglyceride if it is elevated), LDL-cholesterol and both apoE and apoB. The effect of treatment on HDL and its major apolipoprotein, apoA-I, will be monitored. Lipoprotein (a) level is relatively resistant to various forms of medication. Since VLDL receptor gene therapy
20 will lower the apoB-containing lipoproteins (VLDL, IDL and LDL), it is likely that the level of lipoprotein (a), which contains apoB-100 as an essential component, will also be lowered.

25 Example 5: Screening for Compounds Having a
Pharmacological Effect on Human or Mouse VLDL
Receptor

The highest level of expression of the VLDL receptor is found in the heart. The heart also synthesizes lipoprotein lipase (LPL) at a high level.
30 VLDL receptor and LPL, acting separately or in concert, mediate the uptake of lipids (VLDL and fatty acids) from the circulation. These lipids constitute a major source of energy for the heart. Disruption of VLDL receptor function will likely lead to cardiac dysfunction, such as
35 congestive heart failure, cardiomyopathy or arrhythmia.

By using wild-type human or mouse or variant human or mouse VLDL receptors expressed *in vitro*, we can screen for various natural and synthetic compounds that bind to the VLDL receptor (by a modification of the method of Goldstein et al., Methods Enzymol. 98: 241-260, 1983, using apoE-containing lipoproteins instead of LDL as a competing ligand). Compounds identified by *in vitro* binding experiments can be tested for metabolic effects *in vitro*, e.g., do they block or modulate VLDL uptake, or LPL action? Do they modulate HMGCoA reductase activity (by the method of Goldstein et al., Methods Enzymol. 98: 241-260, 1983)? The bioactive compounds can be tested in experimental animals *in vivo*. The compounds found to have beneficial therapeutic effects in congestive heart failure, cardiomyopathy or cardiac arrhythmia may ultimately be used as therapeutic agents in humans or animals.

Example 6: Diagnostic Imaging Utilizing Human or Mouse VLDL Receptor

The high concentration of VLDL receptor in heart may provide a useful handle for developing *in vivo* diagnostic imaging equipment. Natural or synthetic ligands for this receptor can be labeled (e.g., with ^{125}I or other radionuclides) and injected intravenously. The imaging and quantitation of the radionuclide uptake by the heart will allow the structure and function of the heart to be studied *in vivo*. The ligands in such studies include VLDL, apoE-containing vesicles, labeled monoclonal antibodies against the VLDL receptor, or other natural or synthetic compounds identified by *in vitro* binding assays. Labels which are detectable by magnetic resonance imaging, positron emission tomography or computerized axial tomography are also suitable.

Example 7: Use of the Mouse VLDL Receptor

The mouse is a useful animal for both genetic and conventional therapy. It is especially useful for drug screening. The VLDL receptor nucleic acid sequence will be useful in this type of screening. Since the mouse VLDL receptor sequence is highly homologous to the human VLDL receptor, sharing over 95% sequence identity with the latter, many of the methods applicable to the mouse will be applicable to humans. All the uses of the human VLDL receptor discussed in the previous sections can be applied to the mouse VLDL receptor as well. In addition, natural or synthetic compounds that bind to the VLDL receptor, or that modulate VLDL receptor expression can be studied in mouse *in vivo* before they are used for clinical trials in humans.

Example 8: In Vitro Uses of VLDL Nucleic Acid Sequences and Vectors

The human or mouse VLDL nucleic acid sequences or vectors containing such sequences can be used as probes, as is known in the art, in order to screen cDNA or genomic libraries and isolate additional VLDL receptors and/or other as yet unidentified lipoprotein receptors. The human or mouse VLDL nucleic acid sequences or vectors containing such sequences can also be utilized to perform *in situ* hybridizations, as is known in the art, in order to further characterize the tissue distribution of the VLDL receptor or homologous lipoprotein receptors in various species.

Stably transformed or transfected cell lines which express VLDL receptors are useful for the screening of compounds which will specifically bind to these VLDL receptors.

Example 9: Isolation and Cloning of VLDL Receptor Genes

Nucleic acid sequences encoding VLDL receptor genes may be isolated and cloned as is known in the art,

as set forth in, for example, Maniatis, Fritsch and Sambrook, Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982.

5 Probes generated from LDL receptor nucleic acid sequences or VLDL receptor nucleic acid sequences as are known including rabbit, mouse and human may be used. For example, the human and mouse VLDL receptor genes were isolated utilizing probes based on the rabbit VLDL receptor sequence.

10 It will be readily apparent to one skilled in the art that various substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Lawrence C. B. Chan
- (ii) TITLE OF INVENTION: HUMAN AND MOUSE VERY LOW DENSITY LIPOPROTEIN RECEPTORS AND METHODS FOR USE OF SUCH RECEPTORS
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: LYON & LYON
- (B) STREET: 611 West Sixth Street
- (C) CITY: Los Angeles
- (D) STATE: California
- (E) COUNTRY: U.S.A.
- (F) ZIP: 90017
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: IBM MS-DOS (Version 5.0)
- (D) SOFTWARE: WordPerfect (Version 5.1)
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
- Prior applications total,
including application
described below: none
- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Warburg, Richard J.
- (B) REGISTRATION NUMBER: 32,327
- (C) REFERENCE/DOCKET NUMBER: 204/052
- (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: (213) 489-1600
- (B) TELEFAX: (213) 955-0440
- (C) TELEX: 67-3510

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3330 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

```

TTTCCCCTCC CCGCCCCCAC CTTCTTCCTC CTTTCGGAAG GGCTGGTAAC TTGTCGTGCG 60
GAGCGAACGG CGGCGGCGGC GCGGCGGCG GCGGCACCAT CCAGGCGGGC ACCATGGGCA 120
CGTCCGCGCT CTGGGCGCTC TGGCTGCTCG TCGCGCTGTG CTGGGCGCCC CGGGAGAGCG 180
GCGCCACCGG AACCGGGAGA AAAGCCAAAT GTGAACCCCTC CCAATTCCAG TGCACAAATG 240
GTCGCTGTAT TACGCTGTG TGGAAATGTG ATGGGGATGA AGACTGTGTT GACGGCAGTG 300
ATGAAAAGAA CTGTGTAAAG AAGACGTGTG CTGAATCTGA CTTCTGTGTC AACAAATGGCC 360
AGTGTGTTCC CAGCCGATGG AAGTGTGATG GAGATCCTGA CTGCGAAGAT GGTTCAGATG 420
AAAGCCCAGA ACAGTGCCAT ATGAGAACAT GCCGCATACA TGAAATCAGC TGTGGCGCCC 480
ATTCTACTCA GTGTATCCCA GTGTCCTGGA GATGTGATGG TGAAAATGAT TGTGACAGTG 540
GAGAAGATGA AGAAAAGTGT GGCAATATAA CATGTAGTCC CGACGAGTTC ACCTGCTCCA 600
GTGGCCGCTG CATCTCCAGG AACTTTGTAT GCAATGGCCA GGATGACTGC AGCGATGGCA 660
GTGATGAGCT GGAAGTGTCC CCGCCAACCT GTGGCGCCCA TGAGTTCCAG TGCAGCACCT 720
CCTCCTGCAT CCCCATCAGC TGGGTATGCG ACGATGATGC AGACTGCTCC GACCAATCTG 780
ATGAGTCCCT GGAGCAGTGT GGCCGTCAGC CAGTCATACA CACCAAGTGT CCAGCCAGCG 840
AAATCCAGTG CGGCTCTGGC GAGTGCATCC ATAAGAAGTG GCGATGTGAT GGGGACCCCTG 900
ACTGCAAGGA TGGCAGTGAT GAGGTCAACT GTCCCTCTCG AACTTGCCGA CCTGACCAAT 960
TTGAATGTGA GGATGGCAGC TGCATCCATG GCAGCAGGCA GTGTAATGGT ATCCGAGACT 1020
GTGTCGATGG TTCCGATGAA GTCAACTGCA AAAATGTCAA TCAGTGCTTG GGCCCTGGAA 1080
AATTCAGTG CAGAAGTGA GAATGCATAG ATATCAGCAA AGTATGTAAC CAGGAGCAGG 1140
ACTGCAGGGA CTGGAGTGAT GAGCCCCTGA AAGAGTGTCA TATAAACGAA TGCTTGGTAA 1200
ATAATGGTGG ATGTTCTCAT ATCTGCAAAG ACCTAGTTAT AGGCTACGAG TGTGACTGTG 1260
CAGCTGGGTT TGAAGTGA GATAGGAAAA CCTGTGGAGA TATTGATGAA TGCCAAAATC 1320
CAGGAATCTG CAGTCAAATT TGTATCAACT TAAAAGGCGG TTACAAGTGT GAATGTAGTC 1380
GTGGCTATCA AATGGATCTT GCTACTGGCG TGTGCAAGGC AGTAGGCAA GAGCCAAGTC 1440
TGATCTTCAC TAATCGAAGA GACATCAGGA AGATTGGCTT AGAGAGGAAA GAATATATCC 1500
AACTAGTTGA ACAGCTAAGA AACACTGTGG CTCTCGATGC TGACATTGCT GCCCAGAAAC 1560
TATTCTGGGC CGATCTAAGC CAAAAGGCTA TCTTCAGTGC CTCAATTGAT GACAAGGTTG 1620
GTAGACATGT TAAAATGATC GACAATGTCT ATAATCCTGC AGCCATTGCT GTTGATTGGG 1680
TGTACAAGAC CATCTACTGG ACTGATGCGG CTTCTAAGAC TATTTTCAGTA GCTACCCTAG 1740
ATGGAACCAA GAGGAAGTTC CTGTTTAACT CTGACTTGCG AGAGCCTGCC TCCATAGCTG 1800
TGGACCCACT GTCTGGCTTT GTTTACTGGT CAGACTGGGG TGAACCAGCT AAAATAGAAA 1860

```

40

AAGCAGGAAT GAATGGATTG GATAGACGTC CACTGGTGAC AGCGGATATC CAGTGGCCTA 1920
 ACCGAATTAC ACTTGACCTT ATAAAAAGTC GCCTCTATTG GCTTGATTCT AAGTTGCACA 1980
 TGTATCCAG CGTGGACTTG AATGGCCAAG ATCGTAGGAT AGTACTAAAG TCTCTGGAGT 2040
 TCCTAGCTCA TCCTCTTGCA CTAACAATAT TTGAGGATCG TGTCTACTGG ATAGATGGGG 2100
 AAAATGAAGC AGTCTATGGT GCCAATAAAT TCACTGGATC AGAGCTAGCC ACTCTAGTCA 2160
 ACAACCTGAA TGATGCCCAA GACATCATTG TCTATCATGA ACTTGTACAG CCATCAGGTA 2220
 AAAATTGGTG TGAAGAAGAC ATGGAGAATG GAGGATGTGA ATACCTATGC CTGCCAGCAC 2280
 CACAGATTAA TGATCACTCT CCAAAATATA CCTGTTCTTG TCCCAGTGGG TACAATGTAG 2340
 AGGAAAATGG CCGAGACTGT CAAAGTACTG CAACTACTGT GACTTACAGT GAGACAAAAG 2400
 ATACGAACTC AACAGAAATT TCAGCAACTA GTGGACTAGT TCCTGGAGGG ATCAATGTGA 2460
 CCACAGCAGT ATCAGAGGTC AGTGTTCCCC CAAAAGGGAC TTCTGCCGCA TGGGCCATTG 2520
 TTCCTCTCTT GCTCTTAGTG ATGGCAGCAG TAGGTGGCTA CTTGATGTGG CGGAATTGGC 2580
 AACACAAGAA CATGAAAAGC ATGAACCTTG ACAATCCTGT GTACTTGAAA ACCACTGAAG 2640
 AGGACCTCTC CATAGACATT GGTAGACACA GTGCTTCTGT TGGACACACG TACCCAGCAA 2700
 TATCAGTTGT AAGCACAGAT GATGATCTAG CTTGACTTCT GTGACAAATG TTGACCTTTG 2760
 AGGTCTAAAC AAATAATACC CCCGTCGGAA TGGTAACCGA GCCAGCAGCT GAAGTCTCTT 2820
 TTTCTTCCTC TCGGCTGGAA GAACATCAAG ATACCTTTGC GTGGATCAAG CTTGTGTACT 2880
 TGACCGTTTT TATATTACTT TTGTAAATAT TCTTGTCCAC ATTCTACTTC AGCTTTGGAT 2940
 GTGGTTACCG AGTATCTGTA ACCCTTGAAT TTCTAGACAG TATTGCCACC TCTGGCCAAA 3000
 TATGCACTTT CCCTAGAAAG CCATATTCCA GCAGTGAAAC TTGTGCTATA GTGTATACCA 3060
 CCTGTACATA CATTTGTATG GCCATCTGTA AATATCCCAG AGAACAATCA CTATTCTTAA 3120
 GCACTTTGAA AATATTTCTA TGTAAATTAT TGTAAACTTT TTCAATGGTT GGGACAATGG 3180
 CAATAGGACA AAACGGGTTA CTAAGATGAA ATTGCCAAAA AAATTTATAA ACTAATTTTG 3240
 TACGTATGAA TGATATCTTT GACCTCAATG GAGGTTTGCA AAGACTGAGT GTTCAAACTA 3300
 CTGTACATTT TTTTTCAGT GCTAAAAAAT 3330

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	3116 base pairs
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CACCATCCGG GCGGGCAGCA TGGGCACGTC CGCGCGCTGG GCCCTGTGGC TGCTGCTCGC 60

GCTGTGCTGG GCGCCCCGGG ACAGCGGCGC CACTGCAAGC GGAAGAAAG CCAAATGTGA 120
TAGCTCCCAG TTTCAGTGCA CAAATGGCCG CTGCATTACC CTGCTGTGGA AATGTGATGG 180
AGATGAAGAC TGTGCGGATG GCAGCGACGA GAAGAACTGT GTAAAGAAGA CGTGTGCTGA 240
GTCTGACTTC GTGTGCAAAA ACGGCCAGTG TGTTCCTAAC AGATGGCAGT GTGACGGGGA 300
TCCTGATTGC GAAAACGGTT CTGATGAAAG CCCTGAACAG TGCCATATGA GAACATGCCG 360
CATAAATGAA ATCAGCTGTG GCGCCCGTTC TACTCAGTGT ATCCCCGTCT CCTGGAGATG 420
CGATGGTGAA AATGATTGTG ACAATGGAGA AGATGAAGAA AACTGTGGCA ACATAACATG 480
TAGTGACAGT GAGTTCACTT GCTCCAGTGG CCGCTCGCTC TCCAGAAACT TTGTGTGCAA 540
TGGCCAGGAT GACTGTGACG ATGGCAGTGA TGAGCTGGAC TGTGCTCCAC CAACCTGCGG 600
AGCCCACGAG TTCCAGTGCA GCACCTCTTC CTGCATTCCC CTCAGCTGGG TGTGTGATGA 660
TGACGCAGAC TGTTCAGACC AATCAGACGA GTCTCTTGAG CAGTGTGGCC GTCAGCCTGT 720
GATACATACC AAATGTCCTA CCAGTGAGAT CCAGTGTGGC TCTGGCGAGT GCATTACAAA 780
AAAATGGCGG TGTGACGGAG ACCCTGACTG CAAGGACGGC AGCGATGAGG TCAACTGCCC 840
TTCTCGAACC TGCCGACCTG ACCAGTTTGA ATGTGAAGAT GGTAGCTGTA TCCACGGCAG 900
CAGGCAATGC AATGGCATCC GAGACTGTGT TGATGGCTCT GATGAAGTCA ACTGCAAAAA 960
CGTCAATCAG TGCCTGGGCC CTGGAAGTT CAAGTGCAGA AGCGGGGAAT GCATAGACAT 1020
GAGCAAAGTA TGTGACCAGG AACAAGACTG CAGAGACTGG AGTGACGAGC CCCTGAAGGA 1080
ATGCCATATC AACGAATGCC TGGTCAATAA TGGTGGCTGT TCCCATATCT GCAAAGACCT 1140
AGTTATAGGT TATGAGTGTG ATTGTGCAGC TGGGTTTGAA CTGATAGATA GGAAAACCTG 1200
TGGAGATATT GATGAATGCC AAAACCCGGG GATCTGCAGT CAAATTTGTA TCAACTTAAA 1260
AGGCGGTTAC AAGTGTGAAT GTAGTCGTGG CTATCAAATG GATCTTGCCA CTGGCGTGTG 1320
CAAGGCAGTA GGCAAAGAGC CGAGTCTGAT CTTCACTAAT CGAAGAGACA TCAGGAAGAT 1380
TGGCCTAGAG AGAAAGGAAT ACATCCAACCT TGTAGAGCAA CTAAGGAACA CGGTGGCTCT 1440
CGATGCGGAC ATTGCAGCTC AGAAGCTGTT TGGGGCTGAT CTCAGCCAGA AGGCCATCTT 1500
CAGTGCCCTCA ATTGATGACA AGGTGGGTAG ACATTTTAAA ATGATCGACA ATGTCTATAA 1560
TCCTGCAGCC ATTGCTGTTG ATTGGGTGTA CAAGACCATC TACTGGACTG ATGCGGCTTC 1620
TAAGACTATT TCAGTAGCTA CCCTAGACGG AGCCAAGAGG AAGTTCCTGT TTAATTCTGA 1680
CTTGCGAGAG CCTGCCTCCA TAGCTGTGGA TCCGTTGTCG GGCTTTGTTT ACTGGTCAGA 1740
CTGGGGCGAG CCAGCTAAAA TAGAAAAAGC AGGAATGAAT GGATTTGATA GACGTCCTCT 1800
GGTGACGGAG GACATCCAAT GGCCTAATGG AATTACACTC GACCTTGTC AAGCCGCCCT 1860
CTACTGGCTG GATTCCAAGT TGCACATGCT CTCTAGTGTG GACCTGAATG GTCAAGATCG 1920
TAGGATAGTG CTCAAGTCTC TGGAGTTCCT AGCTCATCCT CTTGCACTCA CCATATTTGA 1980
GGATCGCGTC TACTGGATAG ATGGAGAAAA TGAAGCAGTG TACGGTGCCA ATAAATTCAC 2040

TGGGTCAGAG CTGGCCACTC TAGTGAATTC CCTCAATGAT GCCCAAGACA TCATTGTCTA 2100
 CCATGAATC GTCCAGCCGT CAGGTAAAAA CTGGTGTGAA GACGATATGG AGAATGGAGG 2160
 ATGTGAATAT CTCTGCCTGC CAGCACCACA GATCAATGAC CACTCTCCAA AATATACCTG 2220
 TTCCTGTCCC AATGGGTACA ATCTCGAAGA AAATGGACGA GAGTGTCAA GTACTTCAAC 2280
 TCCTGTGACT TACAGTGAGA CAAAAGATAT CAACACAACA GACATTCTAC GAACTAGTGG 2340
 ACTGGTTCTT GGAGGGATCA ATGTGACCAC AGCAGTATCA GAAGTCAGTG TTCCCCCAA 2400
 AGGGACTTCA GCTGCCTGGG CCATCCTTCC TCTCTTGCTC TTAGTGATGG CAGCAGTAGG 2460
 TGGCTACTTG ATGTGGAGGA ATTGGCAACA TAAAAACATG AAAAGCATGA ACTTTGACAA 2520
 TCCTGTGTAC TTGAAGACCA CTGAAGAGGA CCTGTGATA GACATTGGTA GACACAGCGC 2580
 TTCTGTAGGA CACACATACC CAGCAATATC AGTTGTAAGC ACAGATGATG ATCTGGCTTG 2640
 AGTTCTGAAC AAATCTTGGT CTATGAGGTC TACACCAATA ACACCCTACT CTGGAATGGT 2700
 AACAGAGCCA GCGCTGAAGT CTCCTTTCTT CCTCCCATCT GGAAGAACAT CAAGATATCT 2760
 TTTTGTGGAT CAAGTTTGAG TACTTGATCA TTTTATATT ACTTTGTAA ATATTCTTGG 2820
 CCACATTCTA CTTAGCTCTT GGATGTGGTT ACCAAGTATC TGTAACCCTT GAGCCCCTAG 2880
 ACAGTATTGC CATCTCTGGC CAAATATGCA CTTTCCCTAG AAAGCCATAT TCCAGCAATG 2940
 AACGTTGTGC TATAGTGAAT CCCACCTGTA CATACTTGT ATAGGCCACC TGTACATATC 3000
 CCAGAGAACA ATCACTATTC TTAAGCACTT TGAAGATATT TCTATGTAAA TTATTGTAAA 3060
 CTTTTTCAAT GGTGTTGGACA ATGGCAATAG GATAAAACGG GTTACTAAGA TGAAAT 3116

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 846 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Gly Arg Lys Ala Lys Cys Glu Pro Ser Gln Phe Gln Cys Thr Asn Gly
 1 5 10 15
 Arg Cys Ile Thr Leu Leu Trp Lys Cys Asp Gly Asp Glu Asp Cys Val
 20 25 30
 Asp Gly Ser Asp Glu Lys Asn Cys Val Lys Lys Thr Cys Ala Glu Ser
 35 40 45
 Asp Phe Val Cys Asn Asn Gly Gln Cys Val Pro Ser Arg Trp Lys Cys
 50 55 60
 Asp Gly Asp Pro Asp Cys Glu Asp Gly Ser Asp Glu Ser Pro Glu Gln
 65 70 75 80
 Cys His Met Arg Thr Cys Arg Ile His Glu Ile Ser Cys Gly Ala His
 85 90 95
 Ser Thr Gln Cys Ile Pro Val Ser Trp Arg Cys Asp Gly Glu Asn Asp
 100 105 110
 Cys Asp Ser Gly Glu Asp Glu Glu Asn Cys Gly Asn Ile Thr Cys Ser
 115 120 125
 Pro Asp Glu Phe Thr Cys Ser Ser Gly Arg Cys Ile Ser Arg Asn Phe

130		135		140
Val Cys Asn Gly Gln Asp Asp Cys Ser Asp Gly Ser Asp Glu Leu Asp				
145		150		155
Cys Ala Pro Pro Thr Cys Gly Ala His Glu Phe Gln Cys Ser Thr Ser				
		165		170
Ser Cys Ile Pro Ile Ser Trp Val Cys Asp Asp Asp Ala Asp Cys Ser				
		180		185
Asp Gln Ser Asp Glu Ser Leu Glu Gln Cys Gly Arg Gln Pro Val Ile				
		195		200
His Thr Lys Cys Pro Ala Ser Glu Ile Gln Cys Gly Ser Gly Glu Cys				
		210		215
Ile His Lys Lys Trp Arg Cys Asp Gly Asp Pro Asp Cys Lys Asp Gly				
225		230		235
Ser Asp Glu Val Asn Cys Pro Ser Arg Thr Cys Arg Pro Asp Gln Phe				
		245		250
Glu Cys Glu Asp Gly Ser Cys Ile His Gly Ser Arg Gln Cys Asn Gly				
		260		265
Ile Arg Asp Cys Val Asp Gly Ser Asp Glu Val Asn Cys Lys Asn Val				
		275		280
Asn Gln Cys Leu Gly Pro Gly Lys Phe Lys Cys Arg Ser Gly Glu Cys				
		290		295
Ile Asp Ile Ser Lys Val Cys Asn Gln Glu Gln Asp Cys Arg Asp Trp				
305		310		315
Ser Asp Glu Pro Leu Lys Glu Cys His Ile Asn Glu Cys Leu Val Asn				
		325		330
Asn Gly Gly Cys Ser His Ile Cys Lys Asp Leu Val Ile Gly Tyr Glu				
		340		345
Cys Asp Cys Ala Ala Gly Phe Glu Leu Ile Asp Arg Lys Thr Cys Gly				
		355		360
Asp Ile Asp Glu Cys Gln Asn Pro Gly Ile Cys Ser Gln Ile Cys Ile				
		370		375
Asn Leu Lys Gly Gly Tyr Lys Cys Glu Cys Ser Arg Gly Tyr Gln Met				
385		390		395
Asp Leu Ala Thr Gly Val Cys Lys Ala Val Gly Lys Glu Pro Ser Leu				
		405		410
Ile Phe Thr Asn Arg Arg Asp Ile Arg Lys Ile Gly Leu Glu Arg Lys				
		420		425
Glu Tyr Ile Gln Leu Val Glu Gln Leu Arg Asn Thr Val Ala Leu Asp				
		435		440
Ala Asp Ile Ala Ala Gln Lys Leu Phe Trp Ala Asp Leu Ser Gln Lys				
		450		455
Ala Ile Phe Ser Ala Ser Ile Asp Asp Lys Val Gly Arg His Val Lys				
465		470		475
Met Ile Asp Asn Val Tyr Asn Pro Ala Ala Ile Ala Val Asp Trp Val				
		485		490
Tyr Lys Thr Ile Tyr Trp Thr Asp Ala Ala Ser Lys Thr Ile Ser Val				
		500		505
Ala Thr Leu Asp Gly Thr Lys Arg Lys Phe Leu Phe Asn Ser Asp Leu				
		515		520
Arg Glu Pro Ala Ser Ile Ala Val Asp Pro Leu Ser Gly Phe Val Tyr				
		530		535
Trp Ser Asp Trp Gly Glu Pro Ala Lys Ile Glu Lys Ala Gly Met Asn				
545		550		555
Gly Phe Asp Arg Arg Pro Leu Val Thr Ala Asp Ile Gln Trp Pro Asn				
		565		570
Gly Ile Thr Leu Asp Leu Ile Lys Ser Arg Leu Tyr Trp Leu Asp Ser				
		580		585
Lys Leu His Met Leu Ser Ser Val Asp Leu Asn Gly Gln Asp Arg Arg				
		595		600
Ile Val Leu Lys Ser Leu Glu Phe Leu Ala His Pro Leu Ala Leu Thr				
		610		615
Ile Phe Glu Asp Arg Val Tyr Trp Ile Asp Gly Glu Asn Glu Ala Val				
625		630		635
Tyr Gly Ala Asn Lys Phe Thr Gly Ser Glu Leu Ala Thr Leu Val Asn				
		645		650
Asn Leu Asn Asp Ala Gln Asp Ile Ile Val Tyr His Glu Leu Val Gln				

44

Pro	Ser	Gly	660	Asn	Trp	Cys	Glu	Glu	Asp	Met	Glu	Asn	Gly	Gly	Cys
		675	Lys				680					685			
Glu	Tyr	Leu	Cys	Leu	Pro	Ala	Pro	Gln	Ile	Asn	Asp	His	Ser	Pro	Lys
	690					695					700				
Tyr	Thr	Cys	Ser	Cys	Pro	Ser	Gly	Tyr	Asn	Val	Glu	Glu	Asn	Gly	Arg
705					710					715					720
Asp	Cys	Gln	Ser	Thr	Ala	Thr	Thr	Val	Thr	Tyr	Ser	Glu	Thr	Lys	Asp
				725					730					735	
Thr	Asn	Ser	Thr	Glu	Ile	Ser	Ala	Thr	Ser	Gly	Leu	Val	Pro	Gly	Gly
			740					745					750		
Ile	Asn	Val	Thr	Thr	Ala	Val	Ser	Glu	Val	Ser	Val	Pro	Pro	Lys	Gly
	755						760					765			
Thr	Ser	Ala	Ala	Trp	Ala	Ile	Leu	Pro	Leu	Leu	Leu	Leu	Val	Met	Ala
	770				775						780				
Ala	Val	Gly	Gly	Tyr	Leu	Met	Trp	Arg	Asn	Trp	Gln	His	Lys	Asn	Met
785					790					795					800
Lys	Ser	Met	Asn	Phe	Asp	Asn	Pro	Val	Tyr	Leu	Lys	Thr	Thr	Glu	Glu
			805						810					815	
Asp	Leu	Ser	Ile	Asp	Ile	Gly	Arg	His	Ser	Ala	Ser	Val	Gly	His	Thr
			820					825					830		
Tyr	Pro	Ala	Ile	Ser	Val	Val	Ser	Thr	Asp	Asp	Asp	Leu	Ala		
		835					840					845			

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	846 amino acids
(B) TYPE:	amino acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Gly	Lys	Lys	Ala	Lys	Cys	Asp	Ser	Ser	Gln	Phe	Gln	Cys	Thr	Asn	Gly
1			5						10					15	
Arg	Cys	Ile	Thr	Leu	Leu	Trp	Lys	Cys	Asp	Gly	Asp	Glu	Asp	Cys	Ala
			20					25					30		
Asp	Gly	Ser	Asp	Glu	Lys	Asn	Cys	Val	Lys	Lys	Thr	Cys	Ala	Glu	Ser
	35					40						45			
Asp	Phe	Val	Cys	Lys	Asn	Gly	Gln	Cys	Val	Pro	Asn	Arg	Trp	Gln	Cys
	50				55					60					
Asp	Gly	Asp	Pro	Asp	Cys	Glu	Asn	Gly	Ser	Asp	Glu	Ser	Pro	Glu	Gln
65					70				75					80	
Cys	His	Met	Arg	Thr	Cys	Arg	Ile	Asn	Glu	Ile	Ser	Cys	Gly	Ala	Arg
			85					90						95	
Ser	Thr	Gln	Cys	Ile	Pro	Val	Ser	Trp	Arg	Cys	Asp	Gly	Glu	Asn	Asp
			100					105					110		
Cys	Asp	Asn	Gly	Glu	Asp	Glu	Glu	Asn	Cys	Gly	Asn	Ile	Thr	Cys	Ser
	115						120					125			
Ala	Asp	Glu	Phe	Thr	Cys	Ser	Ser	Gly	Arg	Cys	Val	Ser	Arg	Asn	Phe
	130					135					140				
Val	Cys	Asn	Gly	Gln	Asp	Cys	Asp	Asp	Gly	Ser	Asp	Glu	Leu	Asp	
145					150				155					160	
Cys	Ala	Pro	Pro	Thr	Cys	Gly	Ala	His	Glu	Phe	Gln	Cys	Ser	Thr	Ser
			165					170						175	
Ser	Cys	Ile	Pro	Leu	Ser	Trp	Val	Cys	Asp	Asp	Asp	Ala	Asp	Cys	Ser
			180					185					190		
Asp	Gln	Ser	Asp	Glu	Ser	Leu	Glu	Gln	Cys	Gly	Arg	Gln	Pro	Val	Ile
	195						200					205			
His	Thr	Lys	Cys	Pro	Thr	Ser	Glu	Ile	Gln	Cys	Gly	Ser	Gly	Glu	Cys
	210					215					220				
Ile	His	Lys	Lys	Trp	Arg	Cys	Asp	Gly	Asp	Pro	Asp	Cys	Lys	Asp	Gly
225					230					235					240

Ser Asp Glu Val Asn Cys Pro Ser Arg Thr Cys Arg Pro Asp Gln Phe
 245 250 255
 Glu Cys Glu Asp Gly Ser Cys Ile His Gly Ser Arg Gln Cys Asn Gly
 260 265 270
 Ile Arg Asp Cys Val Asp Gly Ser Asp Glu Val Asn Cys Lys Asn Val
 275 280 285
 Asn Gln Cys Leu Gly Pro Gly Lys Phe Lys Cys Arg Ser Gly Glu Cys
 290 295 300
 Ile Asp Met Ser Lys Val Cys Asp Gln Glu Gln Asp Cys Arg Asp Trp
 305 310 315 320
 Ser Asp Glu Pro Leu Lys Glu Cys His Ile Asn Glu Cys Leu Val Asn
 325 330 335
 Asn Gly Gly Cys Ser His Ile Cys Lys Asp Leu Val Ile Gly Tyr Glu
 340 345 350
 Cys Asp Cys Ala Ala Gly Phe Glu Leu Ile Asp Arg Lys Thr Cys Gly
 355 360 365
 Asp Ile Asp Glu Cys Gln Asn Pro Gly Ile Cys Ser Gln Ile Cys Ile
 370 375 380
 Asn Leu Lys Gly Gly Tyr Lys Cys Glu Cys Ser Arg Gly Tyr Gln Met
 385 390 395 400
 Asp Leu Ala Thr Gly Val Cys Lys Ala Val Gly Lys Glu Pro Ser Leu
 405 410 415
 Ile Phe Thr Asn Arg Arg Asp Ile Arg Lys Ile Gly Leu Glu Arg Lys
 420 425 430
 Glu Tyr Ile Gln Leu Val Glu Gln Leu Arg Asn Thr Val Ala Leu Asp
 435 440 445
 Ala Asp Ile Ala Ala Gln Lys Leu Phe Trp Ala Asp Leu Ser Gln Lys
 450 455 460
 Ala Ile Phe Ser Ala Ser Ile Asp Asp Lys Val Gly Arg His Phe Lys
 465 470 475 480
 Met Ile Asp Asn Val Tyr Asn Pro Ala Ala Ile Ala Val Asp Trp Val
 485 490 495
 Tyr Lys Thr Ile Tyr Trp Thr Asp Ala Ala Ser Lys Thr Ile Ser Val
 500 505 510
 Ala Thr Leu Asp Gly Ala Lys Arg Lys Phe Leu Phe Asn Ser Asp Leu
 515 520 525
 Arg Glu Pro Ala Ser Ile Ala Val Asp Pro Leu Ser Gly Phe Val Tyr
 530 535 540
 Trp Ser Asp Trp Gly Glu Pro Ala Lys Ile Glu Lys Ala Gly Met Asn
 545 550 555 560
 Gly Phe Asp Arg Arg Pro Leu Val Thr Glu Asp Ile Gln Trp Pro Asn
 565 570 575
 Gly Ile Thr Leu Asp Leu Val Lys Ser Arg Leu Tyr Trp Leu Asp Ser
 580 585 590
 Lys Leu His Met Leu Ser Ser Val Asp Leu Asn Gly Gln Asp Arg Arg
 595 600 605
 Ile Val Leu Lys Ser Leu Glu Phe Leu Ala His Pro Leu Ala Leu Thr
 610 615 620
 Ile Phe Glu Asp Arg Val Tyr Trp Ile Asp Gly Glu Asn Glu Ala Val
 625 630 635 640
 Tyr Gly Ala Asn Lys Phe Thr Gly Ser Glu Leu Ala Thr Leu Val Asn
 645 650 655
 Ser Leu Asn Asp Ala Gln Asp Ile Ile Val Tyr His Glu Leu Val Gln
 660 665 670
 Pro Ser Gly Lys Asn Trp Cys Glu Asp Asp Met Glu Asn Gly Gly Cys
 675 680 685
 Glu Tyr Leu Cys Leu Pro Ala Pro Gln Ile Asn Asp His Ser Pro Lys
 690 695 700
 Tyr Thr Cys Ser Cys Pro Asn Gly Tyr Asn Leu Glu Glu Asn Gly Arg
 705 710 715 720
 Glu Cys Gln Ser Thr Ser Thr Pro Val Thr Tyr Ser Glu Thr Lys Asp
 725 730 735
 Ile Asn Thr Thr Asp Ile Leu Arg Thr Ser Gly Leu Val Pro Gly Gly
 740 745 750
 Ile Asn Val Thr Thr Ala Val Ser Glu Val Ser Val Pro Pro Lys Gly
 755 760 765

46

Thr	Ser	Ala	Ala	Trp	Ala	Ile	Leu	Pro	Leu	Leu	Leu	Leu	Val	Met	Ala
	770					775					780				
Ala	Val	Gly	Gly	Tyr	Leu	Met	Trp	Arg	Asn	Trp	Gln	His	Lys	Asn	Met
785					790					795					800
Lys	Ser	Met	Asn	Phe	Asp	Asn	Pro	Val	Tyr	Leu	Lys	Thr	Thr	Glu	Glu
				805					810					815	
Asp	Leu	Ser	Ile	Asp	Ile	Gly	Arg	His	Ser	Ala	Ser	Val	Gly	His	Thr
			820					825					830		
Tyr	Pro	Ala	Ile	Ser	Val	Val	Ser	Thr	Asp	Asp	Asp	Leu	Ala		
	835						840					845			

Claims

What is claimed is:

1. Isolated nucleic acid encoding a human or mouse VLDL receptor.
- 5 2. The isolated nucleic acid of claim 1 comprising Sequence ID Nos. 1 or 2.
3. Vector comprising nucleic acid encoding a human or mouse VLDL receptor, said vector being adapted to cause expression of said VLDL receptor.
- 10 4. The vector of claim 3, wherein expression of said human or mouse VLDL receptor results in the production of functional human or mouse VLDL receptor proteins.
- 15 5. The vector of claim 3, wherein said vector comprises a retroviral vector.
6. Vector comprising nucleic acid encoding a VLDL receptor, said vector being adapted to cause expression of said VLDL receptor only in specific tissue.
- 20 7. The vector of claim 6, wherein expression of said VLDL receptor results in the production of functional VLDL receptor proteins.
8. The vector of claim 6, wherein said vector comprises a retroviral vector.
- 25 9. Vector for the expression of a VLDL receptor nucleic acid sequence comprising a tissue-specific promoter, a nucleic acid sequence encoding VLDL receptor, and a post-transcriptional processing control sequence.
- 30 10. The vector of claim 6, wherein said tissue-specific promoter is selected from the group consisting of voluntary muscle specific, liver specific, adipose tissue, specific or cardiac muscle specific promoters.
- 35 11. The vector of claim 10, wherein said tissue-specific promoter is selected from the group of promoters consisting of the retroviral LTR, RSV-LTR, MuV-LTR, cytomegalovirus, apolipoprotein A-I, albumin and its

enhancer, transthyretin, transferrin, skeletal muscle actin or metallothionein.

12. The vector of claim 9, wherein said tissue-specific promoter is from a human.

5 13. The vector of claim 9, wherein said transcriptional processing control sequence comprises a polyadenylation signal sequence.

14. Transfected cell line containing a vector comprising nucleic acid encoding a human or mouse VLDL
10 receptor.

15. The transfected cell line of claim 13, wherein said VLDL receptor is expressed as a cell surface protein.

16. The transfected cell line of claim 14,
15 wherein said VLDL receptor is expressed as a secreted protein.

17. Transformed cell line containing a vector comprising nucleic acid encoding a human or mouse VLDL receptor.

20 18. The transformed cell line of claim 17, wherein said human or mouse VLDL receptor is expressed as a cell surface protein.

19. The transformed cell line of claim 17,
25 wherein said human or mouse VLDL receptor is expressed as a secreted protein.

20. Transgenic non-human animal containing a VLDL receptor.

21. The transgenic animal of claim 18, wherein said transgenic animal is a mammal.

30 22. The transgenic animal of claim 20, wherein said transgenic animal is a mouse.

23. Ligand capable of specifically binding to a VLDL receptor, wherein said ligand has associated with it a detectable label.

35 24. The detectable label of claim 23 selected from the group consisting of a radioactive label, a fluorescent label, a luminescent label, a chemiluminescent

label, a photoactive label, an enzymatically amplifying label, a pH altering label, an electrochemically, volumetrically or gravimetrically detectable label.

25. The ligand of claim 23, wherein said ligand
5 is a monoclonal antibody.

26. A method for introducing a continuous supply of VLDL receptor into an animal or tissue culture, comprising the step of administering an effective amount of the vector of claim 3 or claim 6 to an animal or into
10 said tissue culture.

27. The method of claim 26, wherein the step of administration to an animal comprises injection into a skeletal muscle of the animal.

28. A method of gene replacement, comprising
15 the step of administering an effective amount of said vector of claim 3 or claim 6 to an animal, wherein said VLDL receptor nucleic acid sequence will correct a genetic condition characterized by a defective or nonexistent VLDL receptor.

20 29. The method of claim 28, wherein the step of administration to an animal comprises injection into a skeletal muscle of the animal.

30. Method for preventing or treating a disease or condition characterized by an elevated plasma
25 lipoprotein level comprising the step of elevating the level of VLDL receptor in an animal.

31. The method of claim 30, wherein the level of VLDL receptor is elevated in a specific cell type of an animal.

30 32. The method of claim 31, wherein the level of VLDL receptor is elevated in a hepatocyte of an animal.

33. The method of claim 31, wherein the level of VLDL receptor is elevated in a muscle cell of an animal.

35 34. The method of claim 30, wherein the level of VLDL receptor is elevated in the blood stream of an animal.

35. Method of screening compounds for their pharmacological effects on lipoprotein metabolism comprising the steps of administering a compound to a transgenic animal expressing a VLDL receptor and measuring
5 lipoprotein metabolism in said transgenic animals.

36. Method of administering a nucleic acid sequence encoding a VLDL receptor to an animal comprising the steps of removing cells from said animal, transducing said cells with said VLDL receptor nucleic acid sequence,
10 and reimplanting said transduced cells into said animal.

37. The method of claim 36, wherein said administered nucleic acid sequence encodes a human or mouse VLDL receptor.

38. The method of claim 36, wherein said cells
15 removed from the animal are hepatocytes.

39. The method of claim 36, wherein said cells removed from the animal are muscle cells.

40. Method of administering a VLDL receptor nucleic acid sequence utilizing an *in vivo* approach
20 comprising the steps of administering directly to an animal said VLDL receptor nucleic acid sequence selected from the group of methods of administration consisting of intravenous injection, intramuscular injection, or by catheterization and direct delivery of said VLDL receptor
25 nucleic acid sequence via the blood vessels supplying a target organ.

41. The method of claim 40, wherein said VLDL receptor nucleic acid sequence encodes a human VLDL receptor, further wherein said animal to which the VLDL
30 receptor is administered is a human.

42. The method of claim 40, wherein said target organ is selected from the group consisting of heart, skeletal muscle, adipose tissues, spleen, lung, brain, kidney, testis, adrenal or small intestine.

43. The method of claim 40, wherein said VLDL
35 receptor nucleic acid sequence is administered as naked DNA.

44. The method of claim 40, wherein said VLDL receptor nucleic acid sequence is administered coupled to a ligand which is internalized by a cell through cell surface receptor mediated endocytosis.

5 45. The method of claim 44, wherein said VLDL receptor nucleic acid sequence is coupled to asialoorosomuroid and said cell surface receptor mediated endocytosis occurs through the asialoglycoprotein receptor.

10 46. The method of claim 40, wherein a virus is administered substantially simultaneously.

47. The method of claim 46, wherein said virus is adenovirus.

15 48. The method of claim 40, wherein said VLDL receptor nucleic acid sequence is contained in a viral vector.

20 49. The method of claim 48, wherein said viral vector is selected from the group consisting of papovaviruses, adenovirus, vaccinia virus, adeno-associated virus, herpesviruses and retroviruses of avian, murine or human origin.

25 50. Method of administering a VLDL receptor nucleic acid sequence in a two-component system comprising the steps of administering a packaging cell, wherein said packaging cell produces a viral vector.

51. The method of claim 50, wherein said packaging cell is administered to cells *in vitro*.

52. The method of claim 51, wherein said cells are hepatocytes.

30 53. The method of claim 51, wherein said cells are muscle cells.

54. The method of claim 50 further comprising the step of performing a hepatectomy and administering said packaging cell line to liver *in vivo*.

35 55. Method of administering a VLDL receptor nucleic acid sequence comprising the step of administering a retroviral vector containing said VLDL receptor nucleic

acid sequence, wherein a retroviral envelope glycoprotein is replaced with the G glycoprotein of vesicular stomatitis virus.

56. Method of administering a VLDL receptor nucleic acid sequence comprising the step of administering to an animal an adenovirus vector, wherein an E1 region of said adenovirus vector is replaced with said VLDL receptor nucleic acid sequence and administering said adenovirus vector by a method of administration selected from the group consisting of intravenous injection, intramuscular injection, intraportal injection or intra-arterial injection.

57. Method for isolating additional animal lipoprotein receptor genes or parts of such genes comprising the steps of generating probes from the VLDL Sequence ID Nos. 1 or 2, utilizing said probes to hybridize with a collection of nucleic acid fragments isolated from an animal, and isolating said fragments which hybridize with said probes.

58. The method of claim 57, wherein said additional lipoprotein receptor genes or parts of such genes comprise additional nucleic acid sequences encoding VLDL receptors.

59. Method of enhancing the effect of administering a nucleic acid expression vector encoding a VLDL receptor nucleic acid sequence comprising the steps of administering said VLDL receptor vector and administering a nucleic acid expression vector encoding a lipoprotein lipase nucleic acid sequence.

60. The method of claim 59, wherein said nucleic acid expression vector encoding a lipoprotein lipase nucleic acid sequence is administered substantially simultaneously with said nucleic acid expression vector encoding a VLDL receptor nucleic acid sequence.

61. The method of claim 59, wherein said nucleic acid expression vector encoding a lipoprotein lipase nucleic acid sequence is administered after some

period of time from the administration of said nucleic acid expression vector encoding a VLDL receptor nucleic acid sequence.

5 62. The method of claim 59, wherein said nucleic acid expression vector encoding a VLDL receptor nucleic acid sequence is administered after some period of time from the administration of said nucleic acid expression vector encoding a lipoprotein lipase nucleic acid sequence.

10 63. Method of diagnostic imaging utilizing an imageable compound associated with a ligand which specifically binds to a VLDL receptor.

64. The method of claim 63, wherein said ligand binds specifically to a human or mouse VLDL receptor.

15 65. The method of claim 63, wherein said imageable compound is selected from the group consisting of human perceivable visual labels, electromagnetically detectable labels, radioactive labels, magnetic resonance imaging, positron emission tomography or computerized
20 axial tomography.

TTCCCTCTCTTGCTCTTAGTGATGGCAGCAGTAGGTGGCTACTTGATGTGGCGGAATTGGC
AACACAAGAACATGAAAAGCATGAACTTTGACAATCCTGTGTACTTGAAAACCACTGAAG
AGGACCTCTCCATAGACATTGGTAGACACAGTGCTTCTGTTGGACACACGTACCCAGCAA
TATCAGTTGTAAGCACAGATGATGATCTAGCTTGACTTCTGTGACAAATGTTGACCTTTG
AGGTCTAAACAAATAATACCCCCGTCGGAATGGTAACCGAGCCAGCAGCTGAAGTCTCTT
TTTCTTCCTCTCGGCTGGAAGAACATCAAGATACCTTTGCGTGGATCAAGCTTGTGTACT
TGACCGTTTTTATATTACTTTTGTAAATATTCTTGTCCACATTCTACTTCAGCTTTGGAT
GTGTTTACCGAGTATCTGTAACCCCTGAATTTCTAGACAGTATTGCCACCTCTGGCCAAA
TATGCACCTTTCCCTAGAAAGCCATATTCCAGCAGTGAAACTTGTGCTATAGTGTATACCA
CCTGTACATACATTGTATAGGCCATCTGTAAATATCCCAGAGACAATCACTATTCTTAA
GCACTTTGAAAATATTTCTATGTAAATTATTGTAAACTTTTTCAATGGTTGGGACAATGG
CAATAGGACAAAACGGGTTACTAAGATGAAATTGCCAAAAAAATTTATAAACTAATTTTG
TACGTATGAATGATATCTTTGACCTCAATGGAGGTTTGCAAAGACTGAGTGTTCAAACTA
CTGTACATTTTTTTTCAAGTGCTAAAAAAT

FIGURE 2

mv Mouse VLDLR - total sequences with flanking regions
CACCATCCGGGCGGGCAGCATGGGCACGTCCGCGCGCTGGGCCCTGTGGCTGCTGCTCG
CGCTGTGCTGGGCGCCCCGGGACAGCGCGCCACTGCAAGCGGAAGAAAGCCAAATGT
GATAGCTCCCAGTTTCAGTGCACAAATGGCCGCTGCATTACCCCTGCTGTGGAAATGTGA
TGGAGATGAAGACTGTGCGGATGGCAGCGACGAGAAGAACTGTGTAAAGAAGACGTGTG
CTGAGTCTGACTTCGTGTGCAAAAACGGCCAGTGTGTTCCTAACAGATGGCAGTGTGAC
GGGGATCCTGATTGCGAAAACGGTTCTGATGAAAGCCCTGAACAGTGCCATATGAGAAC
ATGCCGCATAAATGAAATCAGCTGTGGCGCCCGTTCTACTCAGTGTATCCCCGTCTCCT
GGAGATGCGATGGTGAAAATGATTGTGACAATGGAGAAGATGAAGAAAACGTGGCAAC
ATAACATGTAGTGCAGATGAGTTCACCTTGCTCCAGTGGCCGCTGCGTCTCCAGAACTT
TGTGTGCAATGGCCAGGATGACTGTGACGATGGCAGTGTGAGCTGGACTGTGCTCCAC
CAACCTGCGGAGCCACGAGTTCAGTGCAGCACCTCTTCTGCATTCCCCCTCAGCTGG
GTGTGTGATGATGACGCAGACTGTTTCAGACCAATCAGACGAGTCTCTTGAGCAGTGTGG
CCGTCAGCCTGTGATACATACCAAATGTCTTACCAGTGAGATCCAGTGTGGCTCTGGCG
AGTGCAATTCACAAAAAATGGCGGTGTGACGGAGACCCTGACTGCAAGGACGGCAGCGAT
GAGGTCAACTGCCCTTCTCGAACCTGCCGACCTGACCAGTTTGAATGTGAAGATGGTAG
CTGTATCCACGGCAGCAGGCAATGCAATGGCATCCGAGACTGTGTTGATGGCTCTGATG
AAGTCAACTGCAAAAACGTCAATCAGTGCCTGGGCCCTGGAAAGTTCAAGTGCAGAAGC
GGGAATGCATAGACATGAGCAAAGTATGTGACCAGGAACAAGACTGCAGAGACTGGAG
TGACGAGCCCCGTAAGGAATGCCATATCAACGAATGCCTGGTCAATAATGGTGGCTGTT
CCCATATCTGCAAGACCTAGTTATAGGTTATGAGTGTGATTGTGCAGCTGGGTTTGAA
CTGATAGATAGGAAAACCTGTGGAGATATTGATGAATGCCAAAACCCGGGGATCTGCAG
TCAAATTTGTATCAACTTAAAGCGGTTACAAGTGTGAATGTAGTCGTGGCTATCAAA
TGGATCTTGCCACTGGCGTGTGCAAGGCAGTAGGCAAAGAGCCGAGTCTGATCTTCACT
AATCGAAGAGACATCAGGAAGATTGGCCTAGAGAGAAAGGAATACATCCAACCTGTAGA
GCAACTAAGGAACACGGTGGCTCTCGATGCGGACATTGCAGCTCAGAAGCTGTTTGGG
CTGATCTCAGCCAGAAGGCCATCTTCAGTGCCTCAATTGATGACAAGGTTGGTAGACAT
TTTAAATGATCGACAATGTCTATAATCCTGCAGCCATTGCTGTTGATTGGGTGTACAA
GACCATCTACTGGACTGATGCGGCTTCTAAGACTATTTTCAGTAGCTACCCCTAGACGGAG
CCAAGAGGAAGTTCTGTTTAAATCTGACTTGGGAGAGCCTGCCTCCATAGCTGTGGAT
CCGTGTGCGGGCTTTGTTTACTGGTCAGACTGGGGCGAGCCAGCTAAAATAGAAAAAGC
AGGAATGAATGGATTGTATAGACGTCCTCTGGTGACGGAGGACATCCAATGGCCTAATG
GAATTACACTCGACCTTGTCAAAAGCCGCTCTACTGGCTGGATTCCAAGTTGCACATG
CTCTCTAGTGTGGACCTGAATGGTCAAGATCGTAGGATAGTGCTCAAGTCTCTGGAGTT
CCTAGCTCATCCTCTTGCACTCACCATATTTGAGGATCGCGTCTACTGGATAGATGGAG
AAAATGAAGCAGTGTACGGTGCCAAATAAATTCAGTGGGTCAGAGCTGGCCACTCTAGTG
AATTCCTCAATGATGCCCAAGACATCATTGTCTACCATGAACCGTCCAGCCGTCAGG
TAAAACTGGTGTGAAGACGATATGGAGAATGGAGGATGTGAATATCTCTGCCCTGCCAG
CACCACAGATCAATGACCACTCTCCAAAATATACCTGTTCTGTCCCAATGGGTACAAT
CTCGAAGAAAATGGACGAGAGTGTCAAAGTACTTCAACTCCTGTGACTTACAGTGAGAC
AAAAGATATCAACACAACAGACATTCTACGAAC TAGTGGACTGGTTCTGGAGGGATCA
ATGTGACCACAGCAGTATCAGAAGTCAGTGTCCCCCAAAGGGACTTCAGCTGCCTGG
GCCATCCTTCTCTCTTGTCTTGTAGTATGGCAGCAGTAGGTGGCTACTTGATGTGGAG

GAATTGGCAACATAAAAAACATGAAAAGCATGAACTTTGACAATCCTGTGTACTTGAAGA
CCACTGAAGAGGACCTGTGATAGACATTGGTAGACACAGCGCTTCTGTAGGACACACA
TACCCAGCAATATCAGTTGTAAGCACAGATGATGATCTGGCTTGAGTTCTGAACAAATC
TTGGTCTATGAGGTCTACACCAATAACACCCTACTCTGGAATGGTAACAGAGCCAGCGC
TGAAGTCTCCTTTCTTCCTCCCATCTGGAAGAACATCAAGATATCTTTTTGTGGATCAA
GTTTGAGTACTTGATCATTTTTATATTACTTTTGTAAATATTCTTGGCCACATTCTACT
TCAGCTCTGGATGTGGTTACCAAGTATCTGTAACCCCTTGAGCCCTAGACAGTATTGCC
ATCTCTGGCCAAATATGCACTTTCCCTAGAAAGCCATATTCCAGCAATGAACGTTGTGC
TATAGTGAATCCCACCTGTACATACATTGTATAGGCCACCTGTACATATCCCAGAGAAC
AATCACTATTCTTAAGCACTTTGAAGATATTTCTATGTAAATTATTGTAAACTTTTCA
ATGGTTGGGACAATGGCAATAGGATAAAAACGGGTACTAAGATGAAAT

FIGURE 3

Human hvldlr VLDLR Amino acid sequence

GRKAKCEPSQFQCTNGRCITLLWKCDGDEDCVDGSDEKNCVKKTCAESDFVCNNGQCV
SRWKCDGDPDCEDGSDSPEQCHMRTCRIHEISCGAHSTQCIPVSWRCGENDCDSGED
EENCGNITCSPDEFTCSSGRRCISRNFCNGQDDCSDGSDELDCAPPTCGAHEFQCSTSS
CIPISWVCDDADCDQSDSLEQCGRQPVHTKCPASEIQCGSGECIHKKWRCDGDPD
CKDGSDEVNCP\$RTCRPDQFECEDGSCIHGSRQNGIRDCVDGSDEVNCKNVNQLGPG
KFKCRSGECIDISKVCNQEQDCRDWSDEPLKECHINECLVNNGGCSHICKDLVIGYEC
CAAGFELIDRKTCGDIDECQNGICSQICINLKGGYKCECSRGYQMDLATGVCKAVGKE
PSLIFTNRRDIRKIGLERKEYIQLVEQLRNTVALDADIAAQKLFWADLSQKAIFSASID
DKVGRHVKMIDNVYNPAAIAVDWVYKTIYWTDAASKTISVATLDGTRKFLFNSDLREP
ASIAVDPLSGFVYWSWGEPAKIEKAGMNGFDRRPLVTADIQWPNGITLDLIKSRLYL
DSKLHMLSSVDLNGQDRRIVLKSLEFLAHLALTIFEDRVYWIDGENEAVYGANKFTGS
ELATLVNNLNDAAQDIIVYHELVQPSGKNWCEEDMENGCEYLCLPAPQINDHSPKYTCS
CPSGYNVEENGRDCQSTATTVTYSETKDINSTEISATSGLVPGGINVTAVSEVSVPPK
GTSAAWAILPLLLLVMVAAGGYLMWRNWQHKNMKSMNFDNPVYLKTTEEDLSIDIGRHS
ASVGHTYPAISVVSTDDDLA

FIGURE 4

Mouse mvldlr VLDLR Amino acid sequence of the gene

GKKAKCDSSQFQCTNGRCITLLWKCDGEDCADGSDEKNCVKKTCAESDFVCKNGQCV
NRWQCDGDPDCENGSDSPQCHMRTCRINEISCGARSTQCIPVSWRCDGENDCDNGED
EENCGNITCSADEFTCSSGRCVSRNFVCNGQDDCDDGSDELDCAPPTCGAHEFCSTSS
CIPLSWVCDDDADCSDQSDSLEQCGRQPVIIHTKCPTSEIQCGSGECIHKKWRCDGDPD
CKDGSDEVNCPSTRCPDQFECEDGSCIHGSRQCNGIRDVCVDSDEVNCKNVNQCLGPG
KFKCRSGECIDMSKVCDQEQDCRDWSDEPLKECHINECLVNNGGC SHICKDLVIGYEC
CAAGFELIDRKTCGDIDEQNP GICSQICINLKGGYKCECSRGYQMDLATGVCKAVGKE
PSLIFTNRDIRKIGLERKEYIQLVEQLRNTVALDADIAAQKLFWADLSQKAIFSASID
DKVGRHFKMIDNVYNPAAIAVDWVYKTIYWTDAASKTISVATLDGAKRKFLFNSDLREP
ASIAVDPLSGFVYWSDWGEPKIEKAGMNGFDRRPLVTEDIQWPNGITLDLVKSRLYWL
DSKLHMLSSVDLNGQDRRIVLKSLEFLAHLALTIFEDRVYWIDGENEAVYGANKFTGS
ELATLVNSLND AQDIIVYHELVQPSGKNWCEDDMENGGCEYLCLPAPQINDHSPKYTCS
CPNGYNLEENGRECQSTSTPVITYSETKDINTTDILRTSGLVPGGINVTTAVSEVSVPPK
GTSAAWAILPLLLLVM AAVGGYLMWRNWQHKNMKSMNFDNPFVYLKTTEEDLSIDIGRHS
ASVGHTYPAISVVSTDDDLA

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/12911

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C12N15/12 C12N15/85 C12N5/16 C12N15/11 C12N15/63
 C12N15/86

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	HUMAN MOLECULAR GENETICS, vol. 3, no.4, 1994 pages 531-537, J.C. WEBB ET AL. 'Characterization and tissue-specific expression of the human VLDL receptor mRNA' *see the whole document* ---	1
P,X	GENOMICS, vol. 20, 1994 pages 298-300, K. OKA ET AL. 'Human VLDL receptor complementary DNA...' *see the whole document* --- -/--	1

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

6 March 1995

Date of mailing of the international search report

02-05-1995

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Marie, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/12911

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	EUR. J. BIOCHEM., vol. 224, 1994 pages 975-982, K. OKA ET AL. 'Mouse VLDL receptor cDNA cloning...' *see the whole document* ---	1
X	SOMATIC CELL AND MOLECULAR GENETICS, vol. 19, no.6, 1993 pages 557-569, M.E. GAFVELS ET AL. 'Cloning of a cDNA encoding a putative human VLDL/apolipoprotein E receptor...' *see the whole document* ---	1-65
Y	PNAS, vol. 89, 1992 pages 9252-9256, S. TAKAHASHI ET AL. 'Rabbit VLDL receptor...' *see the whole document* ---	1-65
Y	BBRC, vol. 191, no.3, 1993 pages 880-886, M.J.V. HOFFER ET AL. 'The mouse LDL receptor gene: cDNA sequence and exon-intron structure' *see the whole document* ---	1-65
A	J. CLIN. INVEST., vol. 92, no.2, 1993 pages 883-893, S. ISHIBASHI ET AL. 'Hypercholesterolemia in LDL receptor knockout mice and its reversal by adenovirus-mediated gene delivery' *see the whole document* ---	1-65
A	PNAS, vol. 88, 1991 pages 8342-8346, U. BEISIEGEL ET AL. 'Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein' *see the whole document* -----	1-65